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Summary 
 Proopiomelanocortin (POMC) is a precursor protein for many peptide 
hormones such as adrenocorticotropic hormone (ACTH), melanocyte-stimulating 
hormones (MSH) and β-endorphin (β-END). The major tissue that synthesizes 
POMC-derived peptides is the pituitary gland, where POMC is proteolytically 
processed by prohormone convertases (PC) 1 and 2 and by carboxypeptidase E 
(CPE) to cleave POMC to biologically active ACTH and β-END. Non-pituitary 
tissues such as immune cells can also produce β-END. Those cells migrate into 
inflamed tissue where they release opioid peptides and attenuate inflammatory 
pain by activating opioid receptors on peripheral terminals of sensory neurons. 
Overall knowledge about the regulation and production of POMC in immune cells 
is scarce, especially with respect to cells of the adaptive immune system 
(lymphocytes). Under naïve/unstimulated conditions, Pomc mRNA expression may 
be repressed in immune cells. The major questions of the present study were 
whether and how Pomc is repressed in lymphocytes under naïve conditions, which 
cell subsets can be stimulated to express Pomc and whether the post-translational 
processing involves the same proteolytic enzymes as in the pituitary. To study the 
regulatory mechanisms of POMC expression and β-END formation in lymphocytes 
and their subsets (B and T cells), we used isolated cells from lymph node (LN) 
tissue of rats with/without hind paw inflammation induced by intraplantar injection 
of complete Freund’s adjuvant (CFA). 
 The mechanism of Pomc gene repression in naïve lymphocytes was 
investigated on the transcriptional level using a DNA-methyltransferase (RG108) 
and a histone deacetylation inhibitor (trichostatin A). RG108 treatment successfully 
induced the expression of the control transcript Sfrp1 but had no effect on Pomc 
mRNA expression when applied separately or in combination with trichostatin A, 
indicating that neither demethylation nor acetylation are sufficiently derepressive 
with respect to this specific gene or that other mechanisms are involved in Pomc 
repression. Thereupon, the involvement of microRNAs (miRNAs) in Pomc 
repression was studied in naïve lymphocytes by knocking down Dicer using siRNA 
and electroporation. Dicer knockdown diminished the expression of the control 
transcript (IL-10 mRNA) but had no effect on Pomc mRNA, suggesting that 
miRNAs are not involved in the repression of Pomc. Taken together, the nature of 
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Pomc repression in naïve lymphocytes was not fully unravelled, but there is 
evidence that it is not limited to DNA-methylation and does not involve miRNA 
activity. 
 Pomc repression in lymphocytes was switched off upon proper stimulation 
in vivo by CFA-induced inflammation (after 2 h) and by in vitro stimulation with IL-4 
(2 h exposure). Unexpectedly, B cells rather than T cells expressed Pomc mRNA 
in both conditions, while T cells showed Pomc expression only after more 
prolonged exposure to IL-4 (after 24 h). IL-4 thereby activated Pomc expression in 
B cells indirectly. The present findings suggest a T cell-dependent mechanism 
leading to the liberation of one or more factors from IL-4-stimulated T cells, which 
finally drive Pomc gene expression in B cells through JAK-STAT pathway 
activation. Cytokine arrays were performed to identify this/these T cell factor(s) but 
candidate testing in in vitro stimulation assays remained without success. At this 
point the identity of the factor stimulating B cells to produce Pomc mRNA in our IL-
4 in vitro model remains an open question. 
 On the post-translational level POMC needs to be proteolytically processed 
in order to yield β-END. Based on our PCR and immunofluorescence analyses 
PC1 mRNA and protein were expressed under inflammatory conditions and after 
treatment with IL-4 plus conA but not in unstimulated lymphocytes. PC2 mRNA 
and protein expression were generally detectable in naïve/untreated as well as in 
in vivo (CFA) and in vitro stimulated cells (IL-4 plus conA). PC2 protein was 
thereby upregulated in inflammation but in contrast to PC1 showed no changes 
after in vitro stimulation with IL-4 plus conA. PC1 mRNA expression in 
inflammation could be ascribed to B- and T-helper cells, while PC2 mRNA was 
found in all cell subsets including cytotoxic T cells. CPE was undetectable on the 
mRNA and protein level. This may indicate that CPE is not involved in POMC 
processing in lymphocytes. Transcripts of two other potential POMC processing 
enzymes (cathepsin L and aminopeptidase B) were found in naïve and inflamed 
conditions. In accordance with the expression of Pomc mRNA and the presence of 
PC1 and PC2 in in vivo stimulated B cells, β-END levels increased in this cell 
subset in inflammation. Immunofluorescence experiments showed that β-END 
levels were also upregulated in LN cells treated with IL-4 plus conA, which is in 
agreement with the expression of Pomc mRNA and PC1 protein. Taken together, 
these findings suggest that PC1 is crucial for the formation of β-END in 
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lymphocytes, while PC2, cathepsin L, and aminopeptidase B may be of minor 
relevance. 
 To extend our studies to chronic inflammation, the presence of endogenous 
opioid peptides was investigated in a new mouse model of rheumatoid arthritis 
(ACIA-model). We examined Met-enkephalin and β-END in the draining LNs and 
at the site of primary inflammation (joint) using immunohistochemistry, 
radioimmunoassay (RIA), and EIA measurements. Met-enkephalin levels 
increased with increasing cell numbers in draining LN tissue during antigen 
challenges. In established chronic arthritis, however, the amount of Met-
enkephalin in the draining LNs was not different from baseline values. Opioid 
peptide release from explanted knee cells demonstrated that Met-enkephalin and 
β-END are liberated to a similar extent in chronic arthritis. This release could not 
be clearly ascribed to immune cells, pointing towards the involvement of other cell 
types in chronic inflammation. 
 In conclusion, the present studies suggest that the expression of Pomc and 
β-END production in rat lymphocytes involve additional mechanisms to DNA-
methylation, that are overcome under certain circumstances as in acute CFA-
induced inflammation and IL-4 stimulation of mixed cell cultures. Although the key 
factor triggering Pomc mRNA expression in B cells remains unknown, the event 
seems to be cytokine- and JAK/STAT-dependent. The processing of POMC into β-
END seems to be linked to PC1. These findings may help to develop strategies for 
pain therapy by boosting opioid peptide production in immune cells. This might be 
especially interesting for chronic inflammation. 
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Zusammenfassung 
 Proopiomelanocortin (POMC) ist der Vorläufer für mehrere Peptidhomone 
wie z.B. Adrenocorticotrophes Hormon (ACTH), Melanozyten-stimulierendes 
Hormon (MSH) und β-Endorphin (β-END). POMC Peptide werden hauptsächlich in 
der Hypophyse gebildet, wo POMC proteolytisch durch die Prohormonconvertasen 
(PC) 1 und 2 sowie Carboxypeptidase E (CPE) in biologisch aktives ACTH und β-
END prozessiert wird. Immunzellen können ebenfalls β-END bilden. Solche Zellen 
wandern in entzündetes Gewebe ein. Dort können sie Opioidpeptide freisetzen 
und Schmerz durch Aktivierung von Opioidrezeptoren auf peripheren sensorischen 
Neuronen reduzieren. Bisher ist das Wissen über Regulation und Produktion von 
POMC in Immunzellen begrenzt, insbesondere bezüglich Zellen des adaptiven 
Immunsystems (Lymphozyten). Unter naiven/unstimulierten Bedingungen könnte 
die Pomc mRNA Expression unterdrückt sein. Die Hauptfragestellung dieser Arbeit 
ist, ob und wie eine solche Unterdrückung stattfindet, welche Zellsubpopulationen 
zur Pomc Expression stimuliert werden können und ob an der posttranslationalen 
Prozessierung dieselben Enzyme wie in der Hypophyse beteiligt sind. 
 Wir isolierten zunächst Lymphozyten und deren Subpopulationen (B- und T-
Zellen) aus poplitealen Lymphknoten von Ratten mit (bzw. ohne) Complete 
Freund’s Adjuvant (CFA)-induzierter Hinterpfotenentzündung. Um 
Transkriptionsmechanismen zu untersuchen, wurden Inhibitoren der DNA-
Methyltransferase (RG108) und der Histondeacetylierung (Trichostatin A) 
verwendet. RG108 induzierte das Kontrolltranskript Sfrp1, hatte jedoch weder 
alleine noch in Kombination mit Trichostatin A eine Wirkung auf Pomc mRNA 
Expression. Dies weist darauf hin, dass weder Demethylierung noch Acetylierung 
eine entscheidende Rolle spielen. Wir untersuchten dann die mögliche Beteiligung 
von microRNAs (miRNAs) durch Knockdown von Dicer mittels siRNA und 
Elektroporation. Dies reduzierte die Expression des Kontrolltranskripts (IL-10 
mRNA), jedoch nicht Pomc mRNA. Letztendlich konnten wir die Mechanismen 
einer möglichen Pomc Repression in naïven Lymphozyten nicht endgültig 
aufklären, jedoch fanden wir Hinweise darauf, dass weder DNA-Methylierung noch 
miRNA entscheidend daran beteiligt sind. Hingegen fanden wir bereits nach 2 
Stunden erhöhte Pomc Expression in entzündeten Lymphknoten von Ratten mit 
                                                                                                               Zusammenfassung 
IX 
 
CFA-induzierter Hinterpfotenentzündung und nach in vitro Stimulation mit IL-4 (2 
Stunden). 
Unter beiden Bedingungen exprimierten vorrangig B-Zellen Pomc mRNA, während 
T-Zellen Pomc nur nach prolongierter Stimulation mit IL-4 (24 Stunden) bildeten. 
IL-4 aktivierte indirekt die Pomc Expression in B-Zellen nach JAK/STAT 
Aktivierung, vermutlich durch Faktoren, die aus IL-4-stimulierten T-Zellen 
freigesetzt werden. Diese Faktoren konnten mittels Zytokin-Arrays von uns bislang 
nicht identifiziert werden. 
 Mittels unserer PCR und Immunfluoreszenz-Analysen konnten wir zeigen, 
dass PC1 mRNA und Protein unter Entzündungsbedingungen und nach IL-4/conA 
Behandlung nicht jedoch in unstimulierten Lymphozyten exprimiert werden. PC2 
mRNA und Protein waren jedoch sowohl in naïven als auch in stimulierten Zellen 
(nach in vivo CFA oder in vitro IL-4/conA Behandlung) nachweisbar. PC2 Protein 
war infolge der Entzündung hochreguliert, blieb jedoch, im Gegensatz zu PC1, 
nach in vitro Stimulation durch IL-4/conA unverändert. PC1 mRNA Expression in 
der Entzündungssituation erfolgte in B- und T-Helferzellen, während PC2 mRNA in 
allen Subpopulationen einschliesslich zytotoxischen T-Zellen gefunden wurde. 
CPE war nicht nachweisbar und scheint daher nicht an der POMC Prozessierung 
in Lymphozyten beteiligt zu sein. Zwei weitere möglicherweise beteiligte Enzyme 
(Cathepsin L und Aminopeptidase B) konnten in naïven und Entzündungs-
assoziierten Zellen nachgewiesen werden. In Übereinstimmung mit der Expression 
von Pomc mRNA, PC1 und PC2 in in vivo-stimulierten B-Zellen, stieg auch β-END 
in diesen Zellen während der Entzündung an. Immunfluoreszenz-Experimente 
zeigten, dass β-END auch in Lymphozyten nach IL-4/conA Behandlung anstieg, in 
Übereinstimmung mit der Expression von Pomc mRNA und PC1 Protein. Daher 
scheint PC1 wichtig für die Produktion von β-END in Lymphozyten zu sein, 
während PC2, Cathepsin L und Aminopeptidase B weniger vorrangig sind. 
Schließlich untersuchten wir das Vorkommen von Opioidpeptiden auch in einem 
neuen Mausmodell für chronische rheumatoide Arthritis. Wir untersuchten Met-
Enkephalin und β-END in Lymphknoten und in entzündeten Gelenken mittels 
Immunohistochemie, Radioimmunoassay und Enzymimmunoassay. Met-
Enkephalin stieg mit steigenden Zellzahlen in Lymphknoten während der 
Antigenstimulation an. In der etablierten chronischen Arthritis war jedoch die 
Menge an Met-Enkephalin in den drainierenden Lymphknoten unverändert 
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gegenüber Ausgangswerten. Aus Zellen des Kniegelenks wurden ähnliche 
Mengen von Met-Enkephalin und β-END freigesetzt. 
 Zusammengefasst deuten unsere Ergebnisse darauf hin, dass in die 
Expression von Pomc in Lymphozyten Faktoren involviert sind, die unter 
bestimmten Umständen wie z.B. der akuten Entzündung in vivo oder der IL-4 
Stimulation von Zellkulturen in vitro aktiv werden. Obwohl der entscheidende 
Stimulationsfaktor der Pomc mRNA Expression momentan noch unbekannt ist, 
scheint diese abhängig von Zytokinen und JAK/STAT zu sein. PC1 erscheint 
notwendig für die Prozessierung von POMC in β-END. Diese Erkenntnisse 
könnten in neue Strategien zur erhöhten Opioidpeptidproduktion in Immunzellen 
einfließen und zu neuartigen Ansätzen in der Behandlung von akutem und 
chronischem Entzündungsschmerz beitragen. 
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1 Introduction 
1.1 POMC distribution and function 
 POMC is a polypeptide and precursor protein for many peptide hormones 
with diverse biological functions such as adrenocorticotropic hormone (ACTH), 
different melanocyte-stimulating hormones (MSHs), β-endorphin (β-END), etc. 
(Nakanishi et al., 1979). The major tissue that synthesizes POMC is the pituitary 
gland, POMC is produced in the corticotrophs of the pars distalis and in the 
melanotrophs of the pars intermedia (Seidah et al., 1993; Bennett et al., 1992). 
Several non-pituitary tissues also express POMC and related peptides. In the 
brain, POMC-expressing neurons are predominantly present in the arcuate 
nucleus located in the mediobasal hypothalamus (Abrams et al., 1980; Gee et al., 
1983). Moreover, tissues for reproduction such as testis, ovary (Bardin et al., 1987; 
DeBold et al., 1988a; DeBold et al., 1988b), and placenta (Rees et al., 1975; 
Grigorakis et al., 2000)  are shown to express POMC peptides. ACTH, 
β-Lipotropin (β-LPH), γ-MSH, and β-END were shown to  be expressed in adrenal 
gland, kidney, lung, thyroid gland, liver, colon, and duodenum (DeBold et al., 
1988a; DeBold et al., 1988b). POMC, β-LPH, different MSHs, and β-END are in 
skin cells like keratinocytes, melanocytes, and dermal microvascular endothelial 
cells (Schauer et al. 1994; Wintzen et al., 1996; Scholzen et al., 2000).   Immune 
tissues/cells such as spleen (Lolait et al., 1984; Mechanick et al., 1992; Lyons and 
Blalock, 1995), lymph nodes (Cabot et al., 1997; Mousa et al., 2000; Sitte et al., 
2007; Busch-Dienstfertig et al., 2012), and circulating blood leukocytes (Smith and 
Blalock 1981; Harbour et al., 1991) express POMC related peptides. 
 ACTH and the MSHs bind to the melanocortin (MC) receptors 1 to 5 
(Mountjoy et al., 2003). The receptors for β-END are opioid receptors (Li et al., 
1981; Stevens CW, 2011) and can be divided in three classes that have been 
termed mu (µ), delta (δ), and kappa (κ) (Childers, 1993). Each type of opioid 
receptor possesses distinct yet overlapping ligand-binding properties and 
functional characteristics (Corbett et al., 1993). The µ and δ receptors bind the 
opioid peptides to enkephalins and endorphins. Both are G protein-coupled 
receptors (GPCRs) with seven transmembrane domains (Wittert et al., 1996; 
Boston BA, 2000). Upon stimulation with CRH ACTH binds to melanocortin type 2 
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receptors and induces steroidgenesis. Glucocorticoids, androgenic steroids, and 
mineralocorticoids are subsequently released from the adrenal gland (Cowley et 
al., 1999). Appetite and energy expenditure are regulated by the release of α-MSH 
(Cowley et al., 1999). Knock down of melanocortin type 4 receptors  leads to 
adiposity and linear growth  due to the lack of α-MSH signaling   (Butler and Cone, 
2003). Eumelanin is produced in melanocytes by Plasma ACTH and β- or γ-LPH  
leading to a brown coloration of the skin. In the absence of these peptides or 
melanocortin type 1 receptors, pheomelanin is produced leading to red 
pigmentation (Schioth et al., 1999; Ringholm et al., 2004). 
 ACTH-, MSH-, and LPH-related effects such as regulation of body 
temperature, feeding, and emotional states are mediated via melanocortin 
receptors END bind to the opioid receptors and are involved in dampening of pain 
signals (analgesia). (Li et al., 1976). 
 Mice lacking END showed impaired endogenous antinociception  
(Rubinstein et al., 1996) and also involved in the modulation of the immune 
response. (van Epps et al.,1984)  the activity of END is not restricted to opioid 
receptors; END can also act via non-opioid receptors in the nervous and immune 
system (Wollemann et al., 2004). The facts that POMC is expressed in such a 
variety of cell types and that each tissue has its own regulatory mechanisms make 
POMC an important model system for understanding the complex interaction of 
regulatory factors and intracellular mechanisms that establishes the required level 
of gene expression. 
 
1.2 Regulation of POMC and β-endorphin expression in the pituitary gland 
 The Pomc gene expression in the pituitary is largely controlled at the 
transcriptional level, and the formation of β-END is the result of extensive 
proteolytic processing of the precursor molecule. The most important regulatory 
molecules are described in the following two sections. 
1.2.1 Transcriptional regulation 
 There is an involvement of various transcription factors and responsive 
elements in regulating Pomc gene expression in the corticotroph cell, together with 
intracellular signaling pathways acting on the transcription factors. One of the most 
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important transcription factors is the T-box factor TBX19 (Tpit) (Seidah et al., 1993; 
Bennett et al., 1992), which is specifically expressed in corticotroph and 
melanotroph cells (Lamolet et al., 2001). Pomc transcription control by Tpit 
requires the involvement of paired-like homeodomain transcription factor 1 (Pitx1), 
another transcription factor. Moreover, Pomc transcription is sensitive to stress 
hormones such as the corticotropin-releasing hormone (CRH) (Jinet et al., 1994). 
Studies in murine, ACTH-positive AtT-20 cells (pituitary tumor cell line) showed 
that the Pomc promoter activity can also be stimulated by inflammatory cytokines 
such as IL-1β, IL-6, and TNFα (Katahira et al., 1998). Cyclic adenosine 
monophosphate (cAMP)-responsive elements (CRE) and Ca2+-responsive 
elements (CaRE) play an important role in coordinating the degree of Pomc gene 
expression and the rate of secretion of POMC-derived peptides from corticotrophs 
and melanotrophs (Jenks et al., 2009). From the above studies we can say that 
Pomc is regulated by various factors. 
1.2.2 Post-translational regulation 
 Post-translational modifications and processing increase the functional 
diversity of the whole proteome. Post-translational processing of POMC in 
mammals is well studied (Smith et al., 1989; Castro et al., 1997). Studies on 
POMC from rodents, ox, sheep, and humans revealed that in mammals it is 
composed of three major segments: N-POMC, ACTH, and β-LPH. These 
segments are divided from each other by two or more basic amino acid residues, 
which act as cleavage signals and contain one MSH sequence. The β-END 
sequence is always located at the C-terminal end of the β-LPH segment. 
Therefore, mammalian POMC is described as the 3MSH/1END type (Takahashi et 
al., 2013). Studies of POMC in non-mammalian species such as birds (Naudé et 
al., 2006), reptiles (Kobayashi et al., 2007) and fish including teleosts, 
cartilaginous fish, lobe-finned fish, and agnathans (Takahashi et al., 2006), 
showed that the POMC structures are not always the 3MSH/1END type. It was 
also shown that different POMCs are generated in the pars distalis (PD) and pars 
intermedia (PI) of the most primitive vertebrates, the lampreys (Takahashi et al., 
1995). The adult human pituitary gland lacks the pars intermedia and is only 
composed of the anterior lobe containing the pars distalis and pars tuberalis (Asa  
et al., 1995). Here, POMC is predominantly processed into ACTH, and β-LPH 
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(Takahashi et al., 2013). Similar to the human pituitary gland, the adult avian 
pituitary gland is only composed of the pars distalis (Gorbman et al., 1983). 
Several POMC-derived peptides have been isolated from the ostrich (Struthio 
camelus), including ACTH (Li et al., 1978), β-LPH (Naudé et al., 1981), β-END 
(Naudé et al., 1981), γ-LPH (Litthauer et al., 1984), and pro-γ-MSH (Naudé et al., 
1993). The generation of a substantial amount of β-END in the ostrich pituitary 
gland is different from what was observed in the human pituitary, in which β-LPH is 
the predominant form (Holm et al., 1995). Similar to other tetrapods, the Pomc 
gene from snakes and alligators also codes for α-MSH, β-MSH, γ-MSH, and β-
END (Kobayashi  et al., 2007). Together these studies demonstrate that POMC is 
highly conserved across species. However, there seem to be differences amongst 
the POMC-derived products generated in the same tissues from different species, 
which points to the differences in prohormone cleavage. 
 
1.2.2.1 Proteolytic processing of POMC 
 Proteolytic cleavage is a post-translational process commonly employed to 
regulate the cellular proteome and the resultant cellular activity. It occurs at distinct 
amino acid side chains or peptide linkages and is most often mediated by 
enzymatic activity. Such cleavage is especially important for peptide hormones, 
which often are initially synthesized as inactive precursors (e.g. pro-insulin). The 
proteolytic processes involved can vary between different cell types. Peptide 
bonds of proteins are usually cleaved by a class of enzymes called proteases, 
which among others include the group of prohormone convertases (PC). In 
mammals, PCs participate in the formation of biologically active products from 
precursor molecules such as prohormones like pro-insulin through their 
endoproteolytic actions (Bergeron et al., 2000). In endocrine and neuronal cells, 
most peptide hormones and neuropeptides are produced through limited 
endoproteolysis at pairs of basic amino acids during their transport along the 
secretory pathway. The majority of prohormones are cleaved in a cell-specific 
manner by members of the family of calcium-dependent subtilisin-like 
endoproteases, which includes furin, PC1, PC2, PC4, PACE4, PC5/6, 
PC7/LPC/PC8, and SKI-1/S1P (Steiner et al., 1998; Seidah et al., 1999). PC1, 
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unlike furin, PC4, PACE4, PC5-B, PC7, and SKI-1, is predominantly expressed in 
neural and endocrine cells (Seidah et al., 1990; Day et al., 1992). 
 
Figure 1.1 Schematic representation of POMC processing and POMC-cleavage sites of PC1 
and PC2 in the pituitary A. POMC processing begins as the nascent polypeptide chain (pre-
POMC) enters the endoplasmic reticulum with the help of a signal peptide (SIG). Within the ER, the 
signal peptide is removed from the N-terminus, giving rise to a mature POMC. After binding POMC 
to the membrane-bound sorting receptor carboxy peptidase E (CPE) in the trans-Golgi network, 
POMC cleavage occurs within the secretory granules. Adapted from Melanie Busch-Dienstfertig 
(2003). B. In the anterior pituitary gland, POMC is cleaved by PC1 to generate proACTH and β-
LPH. ProACTH is further cleaved by PC1 to generate JP and ACTH. In melanotrophs of the 
intermediate lobe, hypothalamus, and skin PC2 cleaves ACTH to generate ACTH 1–17 and 
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corticotropin-like intermediate lobe peptide (CLIP). PC2 also cleaves β-LPH to generate γ-LPH and 
β-END. Adapted from Pritchard and White (2007). 
 POMC is one of the most extensively studied peptide precursors processed 
in pituitary cells (Mains et al., 1990; Loh et al., 1987). All proteolytic processing of 
human POMC occurs between either the two amino acids lysine (lys) and arginine 
(arg) or between two args. Every lys-arg and arg-arg site within the human 
precursor can be cleaved in vivo, whereas in the mouse and rat, additional arg-lys 
and lys-lys sequences at the N-termini of γ1-MSH and β-MSH respectively, appear 
to be utilized for cleaving POMC (Bicknell et al., 2008). In the pituitary and 
hypothalamus, post-translational proteolysis of POMC is mediated by PC1 and 
PC2 (Seidah et al., 1993). PC1 and PC2 were identified in the early 1990s (Hakes 
et al., 1991; Nakayama et al., 1991; Seidah et al., 1990; 1991; Smeekens et al., 
1990; 1991) and were shown to be involved in the cleavage of POMC and many 
other peptide precursors (Benjannet  et al., 1991; Korner et al., 1991; Nakayama 
et al., 1991; Thomas et al., 1991). Both enzymes are localized in secretory 
vesicles along with the neuropeptide precursors (Christie et al., 1991; Bennett et 
al., 1992). It is known that POMC cleavage begins in the trans-Golgi network 
(TGN) and continues coordinately with the maturation of secretory granules 
(Tanaka et al., 1991; 1992; Schnabel et al., 1989; Tooze et al., 1987). In addition 
to its proteolytic processing, POMC and POMC-derived peptides also undergo 
several other post-translational modifications such as acetylation, amidation, 
phosphorylation, glycosylation, and disulphide linkage formation while residing in 
the Golgi apparatus and secretory vesicles (Christie et al., 1991).  
 In the mammalian pituitary it has been shown that PC1 is expressed in both 
the anterior and the intermediate lobe and that it cleaves POMC mainly at the 
paired basic sites flanking the ACTH sequence. In contrast, PC2 is mainly 
expressed in the intermediate lobe and cleaves POMC in concert with PC1, 
yielding JP, α-MSH, and β-END (Seidah et al., 1992; 1993). Tissue-specific 
proteolytic processes to generate functional peptides have also been described by 
(Takahashi et al., 2013). In corticotrophs, larger peptides such as ACTH are the 
final products, whereas in melanotrophs smaller peptides such as α-MSH are 
predominately generated. As shown in (Fig. 1.1 A), post-translational POMC 
processing begins as the nascent polypeptide chain (pre-POMC) enters the 
endoplasmic reticulum with the help of the signal peptide (SIG) (Cool et al., 1994; 
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Loh et al., 2002). The molecular weight of pre-POMC is approximately 
32 kilodaltons (kDa). Within the ER, the SIG is removed from the N-terminus, 
giving rise to the mature POMC. After binding POMC to the membrane-bound 
sorting receptor carboxy peptidase E (CPE) in the trans-Golgi network, PC1 
cleaves POMC within the secretory granules in the anterior lobe of the pituitary 
(Tanaka et al., 1991; 1992; Cool et al., 1997). The sites Glu-Gly-Lys-Arg, Glu-Phe-
Lys-Arg, and Lys-Asp-Lys-Arg are cleaved by both, PC1 and PC2. Additionally, 
PC2 cleaves Ala-Gln-Arg-Arg and Gly-Lys-Lys-Arg motifs. Because of the limited 
proteolytic action of PC1 at POMC cleavage sites, four different major end 
products corticotropin, β-lipotropin, the joining peptide (JP), and big γ-MSH are 
generated in the anterior lobe (see Fig. 3.1 B). In the intermediate lobe of the 
pituitary, the end products are α-MSH, corticotropin-like intermediate product 
(CLIP), β-MSH, and β-END (Fig. 3.1 B). If both enzymes are present, PC1 
mediates the initial cleavage of POMC into the corticotropin-biosynthetic 
intermediate molecule and β-LPH (Benjannet et al., 1991; Seidah et al., 1999; 
Tanaka et al., 2003). Thereafter, PC2 is able to cleave β-LPH to generate β-MSH 
and β-END (Marcinkiewicz et al., 1993). In humans, β-LPH is processed to γ-LPH 
and β-END, and then γ-LPH is further cleaved by PC2 to β-MSH. After cleavage of 
POMC by PC1 and PC2, the end products have two basic pair residues at their 
C-terminal that are removed by CPE (Douglass et al., 1984; Che et al., 2001). An 
exception is β-END that does not have any C-terminal amino acid residues, since 
it is C-terminally terminated by the STOP codon. In summary the 
formation/generation of POMC-related end products is directed by the enzymatic 
machinery of a cell. 
 
1.2.2.1.1 Activation and inhibition of PC1 and PC2 
 In neuroendocrine and endocrine tissues, activation of mouse PC1 occurs 
auto-proteolytically (Fig. 1.2). When the 94 kDa pre-proPC1 mouse protein enters 
the endoplasmic reticulum, the SIG is cleaved, resulting in the 87 kDa intermediate 
form proPC1 (Lee et al., 2004). This intermediate form is then transported to the 
Golgi apparatus, where it undergoes different post-translational modifications such 
as N-glycosylation (Benjannet et al., 1993). The N-terminal pro-segment is 
processed within the trans-Golgi network and the secretory granules, generating 
                                                                                                                             Introduction 
8 
 
the enzymatically active 66 kDa form (Goodman et al.,1994; Seidah et al.,1999; 
Lee et al., 2004). 
 PC1 is specifically inhibited by proSAAS, an endogenous convertase-
binding protein of 26 kDa belonging to the calcium binding and acidic protein 
family of granins, which in turn belongs to a protein family of regulated secretory 
proteins (Qian et al., 2000; Fortenberry et al., 2002). ProSAAS is predominantly 
expressed in neuronal and pituitary tissues and is processed in parallel to proPC1. 
Cleavage of the signal peptide results in the 23 kDa form SAAS (see Fig. 1.2). The 
inhibitory region of proSAAS comprises 8-12 amino acid residues. The inhibitory 
region of proSAAS is located C-terminally and is completely conserved in humans, 
rats, and mice (Qian et al., 2000). This motif includes a critical lys-arg sequence, 
which determines the inhibitory effect of proSAAS by mimicking substrate 
characteristics. As shown by (Qian et al., 2000), mutation of lys and arg into 
alanine (ala) abolished the inhibition of PC1 activity by proSAAS. Moreover, the 
pro-region and C-terminal region of PC1 show amino acid sequences similar to the 
inhibitory motif of proSAAS and seem to have autoinhibitory properties (Jutras et 
al., 1997; Boudreault et al., 1998). 
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Figure 1.2 Maturation of mouse PC1 Post-translational processing of proPC1 is a multi-step 
procedure that starts in the endoplasmic reticulum. The enzymatically active form of 66 kDa PC1 is 
present in the trans-Golgi network and in secretory granules. In parallel to PC1 its endogenous 
inhibitor proSAAS is processed along the secretory pathway. Modified from Tanaka (2003) and Lee 
et al., (2004). 
 PC2 is also synthesized as an inactive precursor (proPC2) that undergoes 
autocatalytic processing (Fig. 1.3). This processing depends on the presence of 
the neuroendocrine granin 7B2. The 27 kDa precursor pro7B2 specifically binds to 
proPC2 (75 kDa) within the endoplasmic reticulum (Benjannet et al., 1995; Braks 
et al., 1996; Lamango et al., 1996). This complex is then transported to the trans-
Golgi network. Here, the 27 kDa pro7B2 is cleaved into an N-terminal domain of 
21 kDa and a C-terminal domain of 6 kDa by a serine endoprotease (Paquet et al., 
1994). (Martens et al., 1994), demonstrated that the 27 kDa pro7B2 is a potent 
inhibitor of PC2 while the processed 21 kDa form has no inhibitory capacity. 
However, like its precursor, the C-terminal peptide of 7B2 potently inhibits PC2 (Li 
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et al., 2003). The N-terminal 21 kDa form of 7B2 dissociates from proPC2; the 6 
kDa C-terminal domain remains bound to it. In the trans-Golgi network, proPC2 
undergoes an autocatalytic cleavage of the N-terminal pro-domain producing the 
active PC2 of 66 kDa, and the C-terminal domain of 7B2 dissociates from it 
(Lamango et al., 1996; Zhu et al., 1996; Muller et al., 1997; 1999). (Muller et 
al.,1997) demonstrated that rather than promoting proPC2 folding, 7B2 acts as a 
helper protein involved in proPC2 transport and is required in the proPC2 
activation process. Thus, the post-translational regulation of the POMC processing 
is not limited to the presence of PC1 and PC2 but is extended to additional 
regulatory factors such as proSAAS and 7B2. 
 
 
Figure 1.3 Activation mechanism of mouse PC2 Post-translational processing of proPC2 
involves the formation of a proPC2/pro7B2 complex within the endoplasmic reticulum, which is 
transported into the trans-Golgi network where pro7B2 is cleaved. The N-terminal part of 7B2 is 
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released from this complex while the C-terminal part remains associated. In parallel to the 
autocatalytic cleavage of the N-terminal pro-domain of PC2, the C-terminal part of 7B2 also 
dissociates. The enzymatically active form of 66 kDa is released in secretory granules at pH 5. 
Modified from Lehmann (2009). 
1.3 POMC and β-endorphin expression in immune cells 
 As mentioned above, POMC is also expressed and processed in several 
non-pituitary (non-neuroendocrine) tissues such as skin, hypothalamus, testis, 
thyroid gland, placenta, pancreas, gut, kidney, adrenal gland, and liver (Smith et 
al.,1989). POMC-related peptides such as ACTH and β-END were also identified 
in immune cells (e.g. splenic macrophages, peripheral blood lymphocytes) in the 
early 1980s (Smith et al., 1981; Lolait et al., 1984). Under the conditions of painful 
inflammation, immune cells release opioid peptides such as β-END (Busch-
Dienstfertig et al., 2012; Rittner et al., 2006), which can activate opioid receptors 
on peripheral sensory neurons, resulting in the attenuation of pain. 
1.3.1 Opioid peptide containing immune cells in a model of painful 
inflammation 
 Animal models that mimic clinical inflammatory pain use e.g. complete 
Freund's adjuvant (CFA), a suspension of oil and heat-inactivated mycobacteria 
(M. butyricum, M. tuberculosum), to induce an inflammation of peripheral tissue. A 
local subcutaneous unilateral application of CFA into the hind paw of rats induces 
nociceptive behaviour, such as reduced locomotor activity, avoids putting weight 
on the paw, lifting the affected limb from the ground, and permanent flexion of the 
knee joint, indicating spontaneous pain at rest (Stein et al., 1988). Nociceptive 
thresholds to thermal or mechanical stimuli are decreased when heat or pressure 
is applied (thermal and mechanical hyperalgesia), leading to the withdrawal of the 
paw. In parallel, peripheral mechanisms of intrinsic opioid antinociception become 
functionally active within such injured tissues (Stein et al., 2003). Intraplantar 
inoculation with CFA leads to the migration of circulating β-END-containing 
leukocytes to the inflamed tissue (Rittner et al., 2005). Concurrently, opioid 
receptors are upregulated on peripheral endings of sensory neurons (Przewlocki et 
al., 1992; Stein et al., 1996; Mousa et al., 2001). Upon stressful stimulation such 
as a cold water swim or surgery, leukocytes locally liberate β-END to elicit potent 
and clinically relevant opioid receptor-specific analgesia (Stein et al., 1990; 1993). 
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Further analysis determined that β-END is liberated from leukocytes in the 
presence of a variety of releasing stimuli such as CRH (Schafer et al., 1994; Cabot 
et al., 1997), chemokines (Rittner et al., 2006), and catecholamines (Binder et al., 
2004; Mousa et al., 2004). Together these studies suggest that immune cells 
contribute to the endogenous pain control in inflammation by opioid peptide 
release. 
1.3.2 Regulation of POMC expression in lymphocytes 
 As mentioned earlier, POMC-related peptides such as ACTH and β-END 
had already been identified in immune cells (e.g. splenic macrophages, peripheral 
blood lymphocytes) in the early 1980s (Smith et al.,1981; Lolait et al., 1984). 
Macrophages predominantly produced unacetylated, opioid-active β-END, while 
N-acetylated β-END was present in lower amounts as seen in the pituitary (Lolait 
et al., 1986; Westly et al., 1986). At the same time other studies revealed that the 
production of β-END in human peripheral leukocytes can be induced by CRH and 
suppressed by the glucocorticoid analogue dexamethasone (Smith et al., 1986), 
suggesting that the Pomc gene may be expressed and similarly controlled in 
leukocytes and pituitary cells. 
 The Pomc gene comprises three exons that are transcribed into full-length 
Pomc mRNA. Exons 2 and 3 give rise to the pre-propeptide. In neuroendocrine 
cells, the formation of the active peptides is accomplished by entering the 
regulated secretory pathway and involves extensive proteolytic cleavage as 
described above. However, the extensive analysis of several non-pituitary tissues 
demonstrated that these tissues predominantly express shorter Pomc mRNA 
transcripts than found in the pituitary (Bardin et al., 1987). These truncated Pomc 
transcripts comprising about 800 bp of exon 3 but lacking exon 2 were detected  
by several groups in naïve lymphocytes and other immune cell subsets (Lacaze-
Masmonteil et al., 1987; DeBold et al., 1988; Oates et al., 1988; Przewlocki et al., 
1992; van Woudenberg et al., 1993; Cabot et al., 1997; Lolait et al., 1986; Westly 
et al., 1986; Mechanick et al., 1992; Lyons et al.,1997). Therefore, the regulation of 
opioid gene expression and processing in immune cells has not been further 
studied in detail. 
 On the other hand, there is evidence that full-length POMC may be 
expressed in lymphocytes under stimulated and pathological conditions. In a case 
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report of a patient with ectopic ACTH syndrome, lymphocytes in thymic 
hyperplasia were the source of high ACTH production (Ohta et al., 2000). In 
another study, (Buzzetti et al., 1989) detected full-length POMC mRNA in a CD4-
positive, HIV-infected T lymphoma cell line. This Pomc gene expression was 
accompanied by higher ACTH levels in the lymphoma cells than detected in 
normal human peripheral blood mononuclear cells not expressing the full Pomc 
mRNA transcript. Moreover, lymphocytes were shown to express full-length Pomc 
mRNA after stimulation with mitogenic substances such as concanavalin A (Lyons 
et al., 1997) or after infection with pathogens such as the Newcastle disease virus 
(Westly et al., 1986). Lymphocytes were shown to express full-length Pomc mRNA 
after stimulation with IL-4 (Busch-Dienstfertig et al., 2012). Usually, the expression 
of full-length Pomc mRNA appears to be suppressed in mature, unstimulated 
leukocytes, but it can be induced under pathological conditions such as lymphoma 
formation (Buzzetti et al., 1989 and Ohta et al., 2000) or virus infection (Westly et 
al., 1986). Moreover, Pomc transcripts containing the signal sequence necessary 
for correct routing into the regulated secretory pathway are upregulated in 
lymphocytes from rats with painful paw inflammation (Sitte et al., 2007). These 
findings raised the question of whether the lymphocytic expression of Pomc mRNA 
and the processing of its translation products may be different in normal versus 
pathological states. The ultra-structural analysis of macrophages and lymphocytes 
in inflamed paw tissue revealed that β-END was located within vesicular structures 
(Mousa et al., 2004). These findings supported the view that immune cells are 
indeed capable of expressing Pomc derivates containing the signal peptide, an 
essential missing link in the pathway leading to regulated β-END secretion. 
 The difficulties in detecting Pomc mRNA in naïve immune cells as 
described above suggest a repressive mechanism, e.g. methylation of the DNA, 
which is an epigenetic signaling tool to lock genes in the ‘off’ position. Consistently, 
methylation of the Pomc gene was shown to be absent in ACTH-secreting pituitary 
corticotroph cells but strong in non-ACTH-secreting human lymphocytes (Newell-
Price et al., 2001). Whether the methylation status of the Pomc gene defines its 
expression in rat lymphocytes has not been previously analyzed. Another 
possibility is that Pomc mRNA levels in lymphocytes are repressed by rapid mRNA 
degradation through miRNA targeting or by controlling the translation of other 
factors involved in Pomc gene expression (e.g. transcription factors). In the 
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anterior pituitary of mice the conditional knock-out of Dicer1 resulted in the loss of 
mature miRNAs without affecting Pomc mRNA levels (Righi et al., 2010). 
However, since miRNA expression in lymphocytes differs from that in the pituitary, 
a relevance of miRNA in those cells needs to be determined. 
 At present, the repressive mechanisms of Pomc expression in lymphocytes 
have not been investigated in any detail. The following two paragraphs are 
providing background information on DNA methylation, histone acetylation, and 
miRNA which may be of relevance for the negative regulation of Pomc expression. 
1.3.2.1 Transcriptional repression via DNA methylation and histone 
deacetylation 
 DNA methylation at cytosine residues is an important epigenetic 
mechanism that determines gene expression patterns and the stability of 
chromatin. DNA methylation patterns are inherited and tightly correlated with the 
chromatin structure. This essential mechanism regulates cellular differentiation 
during development and maintains the cellular phenotype (Doehring et al., 2011). 
The maintenance of DNA methylation is ensured by DNA (cytosine-5-)-
methyltransferase 1 (DNMT1), which predominantly methylates hemi-methylated 
DNA during replication of proliferating cells. If DNMT1 function is impaired, the 
wrong DNA methylation pattern can easily result in tumours and cancer. Other 
DNA methyltransferases (DNMT3A and DNMT3B) implement the so-called de 
novo methylation of previously unmethylated DNA regions (e.g. during cell 
differentiation). In general, DNA methylation is plastic and can be reversed by DNA 
demethylases. The consequence of DNA methylation is the inhibition of gene 
transcription by blocking transcription factors from binding to the gene and by 
attracting histone deacetylases and other chromatin-remodelling proteins that 
modify histones, resulting in inactive chromatin. Conclusively, active regions of the 
chromatin that enable gene expression are associated with hypomethylated DNA, 
whereas hypermethylated DNA is packaged in inactive chromatin. Histone protein 
modifications either impair the docking of transcription factors onto DNA via 
deacetylation or open the area of DNA to transcription factors through acetylation. 
Histone deacetylation is catalysed via histone deacetylase (HDAC) and results in 
the acetyl group being transferred to coenzyme A. Histone acetylation involves the 
addition of an acetyl group (acetyl–coenzyme A) on lys residues in the N-terminal 
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tail of the protein and on the surface of the nucleosome core, which is catalysed by 
the enzyme histone acetyltransferase (HAT). Acetylated histones and 
nucleosomes represent a type of epigenetic tag within chromatin and result in 
greater levels of gene transcription (Renthal et al., 2008). Histone acetylation is 
therefore a global marker of gene activity. Many transcription factors are regulated 
via acetylation and are specifically targeted by HDACs (Spange et al., 2009). The 
nuclear factor (NF) κB family of transcription factors in particular is dependent 
upon acetylation for full transcriptional activity, whereas deacetylation inhibits the 
transcription of NF-κB target genes. A key regulator of N-methyl-d-aspartate 
receptor (NMDAR) activity, metabotropic glutamate 2 (mGlu2) receptors, is 
transcriptionally regulated by the NF-κB pathway. Activation of (metabotropic 
glutamate receptor 2) mGlu2 receptors causes analgesia in inflammatory and 
neuropathic pain by decreasing NMDAR activity and thereby downregulating 
neurotransmitter release from primary afferent fibres in the dorsal horn of the 
spinal cord (Jones et al., 2005; Simmons et al., 2002; Yang et al., 2002; 2003). 
Selective HDAC inhibitors have been shown to upregulate the expression of 
mGlu2 receptors in the dorsal root ganglion and spinal cord in a mouse model of 
inflammatory pain, thereby causing analgesia (Chiechio et al., 2009). These 
studies suggest that HDACs may be epigenetic targets in the treatment of pain 
(Lotsch et al., 2009). The potential contributory role of epigenetic changes in the 
development of diverse pain phenotypes is particularly intriguing because these 
mechanisms have also been associated with high levels of stress (Wolkowitz et 
al., 2008), depression and aging (Huzen et al., 2008), major factors associated 
with increased pain sensitivity. For instance HDACs, which silence certain genes, 
were found to play a role in pain-signal transmission in the spinal cord (Bai et al., 
2010). Specifically, class IIa HDACs were upregulated. 
1.3.2.2 Post-transcriptional repression by miRNA 
 MiRNAs are a family of endogenously derived, non-coding RNAs that 
epigenetically regulate gene expression (He et al., 2004). Rosalind Lee et al., 
1993) discovered that the expression of the LIN-14 protein is regulated by a small 
RNA derived from the lin-4 gene in Caenorhabditis elegans. Meanwhile, miRNA 
expression has been studied in several species and cell types, and it is becoming 
apparent that they are important post-transcriptional gene regulators. Mature 
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miRNAs are formed from their immature precursors (Kim et al., 2009). miRNA 
biogenesis is therefore realized by a protein machinery that involves the class III 
endoribonuclease Dicer, which is well conserved among eukaryotes. The 
biogenesis of miRNA begins with its transcription from genomic DNA containing 
the miRNA sequences via RNA polymerase II. The transcription product was 
termed pri-miRNA, which is further processed into pre-miRNA by a nuclear protein 
complex called the microprocessor complex. Pre-miRNAs are transported from the 
nucleus to the cytoplasm by exportin-5. In the cytoplasm, the pre-miRNAs are 
loaded onto a protein complex composed of Dicer, argonaute-2, the TAR RNA 
binding protein (TRBP), and other proteins known as the RNA-induced silencing 
complex (RISC) (Koscianska et al., 2011). RISC-loaded pre-miRNAs are cleaved 
to their mature form (approximately 22 nucleotides) by Dicer. The mature miRNAs 
are capable of binding their cognate mRNA target through miRNA-mRNA 
interactions, while they are still associated with the RISC. The miRNA-mRNA 
interactions are established through complementary base pairing between a 
sequence on the miRNA called the seed region and the 3’ untranslated region on 
the target mRNA, leading to translational inhibition and/or mRNA degradation (Krol 
et al., 2010). However, miRNAs do not target specific mRNAs and do not have to 
perfectly match the sequence of their targets; Therefore, they can coordinate the 
expression of large sets of genes (Bartel et al., 2009). It is estimated that up to 
60% of the human genome may be regulated by miRNAs (Friedman et al., 2009). 
1.3.2.3 Proteolytic processing of POMC in lymphocytes 
 POMC alone or co-localized with PC1, PC2, and CPE was detected in 
circulating leukocytes, particularly under conditions of painful inflammation in 
animals (Smith et al., 2003; Mousa et al., 2004). To date there are only a few 
studies that have investigated the presence of prohormone convertases 
specifically in lymphocytes. (Lansac et al., 2006), observed PC1 and PC2 mRNA 
expression in the spleen of rats using in situ hybridization histochemistry, 
demonstrated that macrophages and lymphocytes contained these enzymes. 
Basal expression of PC1 mRNA was seen in the macrophage-rich red 
pulp/marginal zone areas of the spleen. Moreover, PC1 and PC2 mRNA 
expression was inducible within germinal centres (B lymphocytes) after in vivo lipo-
polysaccharide-treatment. These findings point towards a differential expression of 
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the two proteolytic enzymes in different types of immune cells. (Mousa et al., 
2004), further analysed the expression of PC1, PC2, 7B2, and CPE in blood 
leukocytes at the protein level using western blotting and immunohistochemistry. 
In normal rats, the proteolytic enzymes were detectable in granulocytes and 
monocytes/macrophages but not in circulating lymphocytes. From previous 
studies, we have seen that after induction of a CFA-inflammation in the paw, the 
amount of PC1, PC2, POMC, and β-END increased in lysates of blood leukocytes, 
and proteolytic enzymes were then detectable in granulocytes, 
monocytes/macrophages, and in circulating lymphocytes. These findings raised 
the questions of whether the cells of lymph nodes draining paw tissue also express 
enzymatically active PC1 and PC2 and whether these enzymes are upregulated 
and involved in the processing of POMC under conditions of painful inflammation. 
1.4 Antigen- and collagen-induced arthritis (ACIA) models 
 Chronic disorders accompanied by inflammation are the most common 
diseases of aging and represent the greatest health threat (Tabas et al., 2013). 
Such disorders include rheumatoid arthritis (RA); Chronic joint inflammation and 
pain are the two main symptoms in patients with RA and are associated with 
significant morbidity (Firestein et al., 2005). RA is a chronic autoimmune disease 
characterized by infiltration of leukocytes into the synovial and periarticular tissues 
(Wipke et al., 2001; Liew et al., 2005; Coelho et al., 2008), which results in the 
destruction of cartilage and bone (Firestein et al., 2003). Although significant 
progress has been made regarding anti-inflammatory therapies, chronic pain is still 
an unresolved clinical problem (Perrot et al., 2013). Inflammatory mediators are 
released into the inflamed tissue in response to inflammatory stimuli that in turn 
release a cascade of cytokines such as tumour necrosis factor (TNF)-α and IL-1β 
that further drive the inflammatory reaction (Cunha et al., 2005; Verri et al., 2006). 
Therefore, cytokines such as TNF-α and IL-1β are interesting therapeutic targets 
to treat RA patients (Scott et al., 2006). Problems associated with anti-cytokine 
therapies are expensive and the need to be administered via the parenteral route. 
Additionally, many patients fail to respond to TNF-α (Moreland et al., 1997) or IL-
1β (Jiang et al., 2000) blockade. Standard analgesic treatments such as 
nonsteroidal anti-inflammatory drugs or steroids often exhibit detrimental side 
effects in the long-term use (e.g. gastrointestinal ulcers, bleeding, myocardial 
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infarction, stroke, infections) (Huscher et al., 2009; Trelle et al., 2011). Thus, there 
is an urgent need for alternative therapeutic approaches. Since opioids can 
interfere at different stages with the cascade of pro-inflammatory events in 
peripheral tissues (Stein et al., 2011; 2013), we set out to investigate endogenous 
opioids in an animal model of chronic arthritis. Antigen-collagen-induced arthritis 
(ACIA) is a new mouse model representing key features of RA such as chronicity, 
cartilage and bone erosion, and prominent autoimmune responses against 
autologous collagen II, vimentin, and ACPA (Baddack et al., 2013).  Immune cells 
infiltrating inflamed tissue can potently reduce pain by liberating opioid peptides 
such as enkephalins, endorphins, and dynorphin (Stein et al., 2011; 2013; Rittner 
et al., 2005). Such mechanisms have been predominantly investigated in animals 
and humans with acute inflammatory injuries as already mentioned above, but 
their relevance in chronic inflammation is unknown. In acute stages of ACIA, the 
cellular infiltrate is mainly composed of neutrophils, macrophages, and 
mononuclear cells (lymphocytes), while mononuclear and fibroblast-like cells are 
predominant at chronic stages (Baddack et al., 2013). This raises the question of 
whether opioid peptides are also present under chronic inflammatory conditions, 
laying the basis for opioid-mediated antinociception. 
1.5 Objectives 
 POMC processing occurs in peripheral tissues including immune cells. One 
of the end products is the opioid peptide β-END. Following its release, β-END can 
activate opioid receptors on peripheral sensory neurons in order to inhibit pain 
within inflamed tissue. However, our knowledge of the regulation of POMC 
expression and its processing in immune cells such as lymphocytes is poor to 
date. In order to provide insight into the regulatory mechanism of POMC 
expression as well as into the relevance of PC1 and PC2 for the formation of β-
endorphin in lymphocytes, the present study focused on the following specific 
aspects: 
1) Transcriptional regulation of POMC in lymphocytes. 
2) Repression and expression of POMC in native lymphocytes. 
3) POMC Processing enzymes in lymphocytes. 
4) Endorphin production in lymphocytes. 
5) Opioid peptides in mice with chronic arthritis. 
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 Pomc gene transcription in lymphocytes can be regulated by various 
mechanisms such as methylation, acetylation, and miRNA. Our aim was to see the 
involvement of these mechanisms in the regulation of Pomc gene expression. 
Methylation status would be investigated using bisulfite sequencing, if this strategy 
does not yield a conclusive result, we would investigate using a DNA-
methyltransferase inhibitor to see if it effects Pomc gene expression. To address 
the question of acetylation we would use a histone deacetylation inhibitor to study 
whether Pomc is deacetylated. To study the involvement of miRNA in Pomc 
repression, we intended to knock down Dicer using siRNA, as Dicer is very 
important for the maturation of miRNA. Therefore in the absence of Dicer, there 
would be no miRNA so that we could see how the absence of miRNA would have 
an effect on Pomc gene expression. 
 Pomc repression in lymphocytes was switched off upon proper stimulation 
in vivo by CFA-induced inflammation (after 2 h) and by in vitro stimulation with IL-4 
(2 h exposure). The present aim of the study was to see which subsets of 
lymphocytes would express Pomc. It is known that Pomc in lymphocytes is 
expressed upon IL-4 stimulation via JAk/STAT pathway. Our aim is to study which 
pathway is involved in the subsets of lymphocytes. Lymphocytes would be 
separated into subsets using MACS separation columns, and supernatant transfer 
experiments would be performed to see which subsets are responsible for 
expression of Pomc. If a specific subset is responsible for pomc expression, we 
would investigate the signalling pathway involved. Then using cytokine array we 
would look for the factor that stimulates the expression of Pomc. 
 In the pituitary, POMC is proteolytically cleaved by PC1, PC2, and CPE into 
β-END. Our aim was to investigate whether the same proteolytic enzymes are 
involved in the cleavage of POMC in lymphocytes. To answer this question we 
would study the expression of PC1, PC2, and CPE in both in vitro (IL-4) and in 
vivo (CFA) using PCR and immunofluorescence or western blot. Then we would 
measure β-END levels in both the in vitro (IL-4) and in vivo (CFA) studies using 
radioimmunoassay (RIA) and immunofluorescence. We would then study the 
functionality of proteolytic enzymes via knockdown using siRNA of the specific 
enzymes and also measure the β-END levels to see if they are affected by 
knocking down a particular processing enzyme. 
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 To extend our studies to chronic inflammation, the presence of endogenous 
opioid peptides would be investigated in a new mouse model of rheumatoid 
arthritis (ACIA-model). We would measure Met-enkephalin and β-END in the 
draining LNs and at the site of primary inflammation (joint) using 
immunohistochemistry, RIA and EIA measurements. 
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2 Materials and Methods  
2.1 Materials 
2.1.1 Enzymes 
Table 2.1 List of enzymes 
Name Company 
50× Advantage 2 polymerase mix Clontech Laboratories 
Avian myeloblastosis virus reverse transcriptase (AMV) Roche  
DNAse QIAGEN 
RNAse inhibitor Roche  
Fast start DNA master plus SYBR green 1 Roche 
Thermus aquaticus (Taq) polymerase Roche  
2.1.2 Radioactively labelled peptides 
Table 2.2 List of radioactively labelled peptides 
Name Company 
(125 I)rat β-endorphin Peninsula Laboratories 
(125 I) Met-enkephalin Peninsula Laboratories 
2.1.3 Antibodies 
Table 2.3 List of antibodies 
Antibody Application Company 
Anti-mouse CD8a (LY2.2) For in vivo 
depletion 
Leinco Technologies 
Anti-rabbit IgG, peroxidase-conjugated IHC Vector Laboratories 
Donkey anti-mouse IgG, FITC IF Vector Laboratories 
Rat IgG2b Isotype 
control for in  
Leinco Technologies 
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vivo depletion 
Goat anti-rabbit IgG, biotinylated IHC Vector Laboratories 
Goat anti-rabbit, Texas red-conjugated IF Vector Laboratories 
Mouse 3E7 (pan opioid) FC Gramsch Laboratories 
Mouse anti-rat CD3 (G4.18) PE/FITC  FC Pharmingen 
Mouse anti-rat CD4 (Ox-35) PE/FITC  FC Pharmingen 
Mouse anti-rat CD4 microbeads MACS Miltenyi Biotec 
Mouse anti-rat CD45 microbeads MACS Miltenyi Biotec 
Mouse anti-rat CD45RA  microbeads MACS Miltenyi Biotec 
Mouse anti-rat CD8 microbeads  MACS Miltenyi Biotec 
Mouse anti-rat MHC class II MACS Miltenyi Biotec 
Rabbit anti-rat beta-endorphin RIA Peninsula Laboratories 
Rabbit anti-rat beta-endorphin IgG  IF, IHC Peninsula Laboratories 
Rabbit anti-rat met-enkephalin IgG IF, IHC Peninsula Laboratories 
Prohormone convertase 1/3 IF Donald Steiner, Chicago 
Prohormone convertase  2 IF Donald Steiner, Chicago 
Dicer IF Abcam 
ProSAAS IF Abcam 
 
Abbreviations used: IF = immunofluorescence, IHC = immunohistochemistry, FITC = fluorescein 
isothiocyanate conjugate, FC = flow cytometry, MACS = magnetic cell separation, RIA = 
radioimmunoassay. 
2.1.4 siRNA 
Table 2.4 List of siRNA 
siRNA name Application Company 
Control siRNA sc-37007 Electroporation Santa Cruz  
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Dicer(rat) sc-270275 Electroporation Santa Cruz 
PCSK1 (rat) sc-270276 Electroporation Santa Cruz 
PC2 (rat) sc-270277 Electroporation Santa Cruz 
2.1.5 Chemicals, kits 
Table 2.5 List of chemicals and kits 
Name Company 
β-mercaptoethanol C. Roth GmbH 
Agarose LE Roche  
Ampicillin E. Merck AG 
Bovine serum albumin (BSA) Sigma-Aldrich 
Bovine collagen type II MD Bioproducts, Zurich 
Bordetella pertussis toxin (PTX) Calbiochem, La Jolla, CA 
Bradford reagent Biorad 
Bromphenol blue Sigma-Aldrich 
Collagenase II Sigma-Aldrich 
Complete Freund’s adjuvant (CFA) Calbiochem 
Concanavalin A (con A) Sigma-Aldrich 
Cytokine array Ray Bio 
Deoxy-nucleotide triphosphate mix (dNTP) Roche  
Dextran 500 Amersham Pharmacia Biotech 
Dithiothreitol (DTT) Sigma-Aldrich 
Donkey serum Jacksons Immuno Research 
Laboratories 
DNA molecular weight markers (100 bp) Roche 
                                                                                                           Materials and Methods 
24 
 
Ethanol (99%) C. Roth GmbH 
Ethidium bromide Sigma-Aldrich 
EZ DNA methylation kit Zymo research 
Fast Start DNA Master SYBR Green I Kit Roche 
Fetal bovine serum (FBS) Biochrom AG 
Glycerol Sigma-Aldrich 
Glycine Sigma-Aldrich 
Goat serum Vector Laboratories 
Horse serum Biochrom 
Hyaluronidase Sigma-Aldrich 
Imidazole Sigma-Aldrich 
Interleukin (IL-2 rat, recombinant) R & D Systems 
Interleukin (IL-4 rat, recombinant) R & D Systems  
Interleukin (IL-6 rat, recombinant) R & D Systems 
Interleukin (IL-6 Rα rat, recombinant) R & D Systems 
Interleukin (IL-10 rat, recombinant) R & D Systems 
Isofluran Curamed ((1-Chlor-2,2,2-trifluorethyl) difluormethylether) Rhodia 
JAK II inhibitor Calbiochem 
Leptin Sigma-Aldrich 
Leukaemia inhibitory factor (LIF) Sigma-Aldrich 
mBSA (methylated bovine serum albumin) Sigma-Aldrich 
Methanol C. Roth GmbH 
Normal rabbit IgG Sigma-Aldrich 
pan-JAK inhibitor Calbiochem 
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Paraformaldehyde (PFA) Sigma-Aldrich 
Penicillin/streptomycin (10,000 U / 10,000 µg/ml) Biochrom 
Phosphate buffered saline (PBS, sterile, 0.1 M, pH 7.4) GIBCO Invitrogen Corporation 
Primer dT for cDNA synthesis (oligo dT) Roche 
Pyridon 6 Calbiochem 
Qiaquick gel extraction kit QIAGEN 
rat-beta-endorphin kit Peninsula Laboratories 
RB108 Calbiochem 
RNAse-free DNAse (1500 U/µl) Macherey- Nagel 
Nucleospin RNA II Macherey- Nagel 
RPMI-1640 medium (+Glutamax I) GIBCO Invitrogen Corporation 
Saponin from Quillaja bark Sigma-Aldrich 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich 
STAT-5 inhibitor Calbiochem 
Tissue-Tek compound OCT Miles 
Trishydroxymethylaminomethane (Tris) Sigma-Aldrich 
Triton X-100 (t-Octylphenoxy-poly-ethoxyethanol) Sigma-Aldrich 
Trypan blue stain (0.4%) GIBCO Invitrogen Corporation 
Trypsin/EDTA GIBCO Invitrogen Corporation 
Xylene cyanole FF Sigma-Aldrich 
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2.1.6 Oligodeoxynucleotides 
Oligonucleotides purchased from TIBMOLBIOL. Primer names, sequences, base pairs, melting 
temperature (Tm) and primer type are given. Names indicate the target gene.  
Table 2.6 List of oligodeoxynucleotide sequences 
Name Sequence (5`- to -3`) bp Tm (°C) Primer 
type 
POMC2ex2se TGGCCCTCCTGCTTCAGAC 19 63.8 Se 
3POMCex3as CTCACTGGCCCTTCTTGTGC 20 63.2 As 
rat-RPL19b-as TGCTCCATGAGAATCCGCTTG 21 65.8 As 
ratRPL19b-se AATCGCCAATGCCAACTCTCG 21 66.7 Se 
Rat GAPDH-se ACAGTCAAGGCTGAAAATGG 20 54.5 Se 
Rat GAPDH as CATGAGCCCTTCTACAATGC 20 54.5 As 
PC2 primer se GAGAGGAGACCTGAACATCA 20 50.4 Se 
PC2 primer as GCAAGCCCTTCTGTGGTGCA 20 63.5 As 
7B2 se AATCCAGCATTCGCTTATAG 20 50.7 Se 
7B2 as TAGGAATATTGTCGCCAGTC 20 50.9 As 
PC1/3 se AATCCTGTAGGCACCTGGAC 20 55.8 Se 
PC1/3 as GGAGTTTTTGGGTACCAGGA 20 55.6 As 
PC2 FW (new) GGGCCCACAGACAACGGGA 20 66 Se 
PC2 RV (new) GCCGTCGTTGATGGCCGAGT 20 68 As 
Rat Dicer FW GTGGCGCTGAGACCGCAACT 20 65.3 Se 
Rat Dicer RV AGGGTCCCAGGACGACCAGC 20 65.0 As 
Rat proSAAS FW GGCCGGGGGCGTAGGCCTTT 20 71.1 Se 
Rat proSAAS RV CGCCAGCTCCTGCACCGCAC 20 70.9 As 
Rat Ctsl1 FW 
(cathepsin L) 
TGTGGCTAACGACACAGGGT 20 61.4 Se 
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Rat Ctsl1 RV 
(cathepsin L) 
GCAGTGGTTGTTCCGGTCTT 20 60.8 As 
Ap-B (RNPEP) FW 
(aminopeptidase B) 
GGCCATTGGAGATCTGGCTT 20 60.11 Se 
Ap-B (RNPEP) RV 
(aminopeptidase B) 
TTGGCATTGGTGACCAGGTT 20 60.11 As 
IL-10 F1 TGGCTCAGCACTGCTATGTT 20 59.67 Se 
IL-10 R1 (rat) GGCTTGGCAACCCAAGTAAC 20 59.68 As 
2.1.7 Other materials 
Table 2.7 List of instruments used 
Instruments Company 
Cell counting chamber Glaswarenfabrik Karl Hecht 
Cell scraper Sigma-Aldrich 
Cell strainer (70 µm mesh) BD Biosciences Discovery Labware 
Cryostat (Microm HM560) MICROM 
Electrophoresis apparatus (Power Pac 300) Bio-Rad Laboratories 
Flow cytometry apparatus (FACS Calibur) Becton-Dickinson 
Fluorescence microscope Carl Zeiss Mikroskope 
Gamma-Counter, Wallac Wizard 1470 Wallac 
Heraeus incubator Kendro 
Kryo tubes Nunc  
Laminar flow (Hera Safe) Kendro 
Microscope (Axiovert 25) Carl Zeiss Mikroskope 
Photometer (Gene Quant II RNA/DNA calculator) Pharmacia Biotech 
pH meter Mettler Toledo 
Separation columns (mean size) Miltenyi Biotec 
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Separator (VarioMACS™) Miltenyi Biotec 
Sterile filters Millipore  
Real time PCR Eppendorf 
Thermocycler (Mastercycler personal) Eppendorf 
Tubes (15 and 50 ml) Falcon 
Twin tech real time PCR plates 96 well Eppendorf 
Ultrapure Water Systems (Direct-Q™ 5) Millipore  
UV-Light (Macro Vue UV=25) Hoefer 
2.2 Methods 
2.2.1 Animals and animal housing 
 Experiments were carried out using male WISTAR rats (Janvier, France), 
(200-250)g and female Balb/c mice (Janvier, France 10–14 weeks of age). They 
were housed in cages lined with ground corncob bedding. Standard laboratory 
rodent chow and tap water were available ad libitum. Room temperature was 
maintained at 22°C and a relative humidity between 40% and 60% was 
maintained. A 12/12 hr (7 a.m. / 7 p.m.) light/dark cycle was used. Experiments 
were approved by the animal care committee of the State of Berlin and strictly 
followed the guidelines of the International Association for the Study of Pain 
(Zimmermann 1983). 
2.2.2 Animal models 
2.2.2.1 CFA-induced inflammation 
Rats received an intraplantar (i.pl.) injection of 0.15 ml complete Freund’s 
adjuvant (CFA) into the right hind paw under brief isoflurane anaesthesia. This 
inflammatory model is routinely used in our own as well as in other research 
groups (Stein et al., 1988; Barber et al., 1992). From 2-96 hours after CFA 
injection, there is a swelling of the paw tissue, hyperaemia and hyperalgesia 
(animals showing an increased sensitivity to pain). During the observation period 
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the inflammation remained confined to the right paw and no significant changes 
were observed in feeding behaviour, body weight, body temperature, and general 
activity range compared to untreated animals (Stein et al., 1988). Control animals 
remained untreated. 
2.2.3 Rat cell and tissue preparation 
Using an overdose of inhalation anaesthesia (isoflurane), rats were killed, 
then decapitated and then the skull and brain overlying the pituitary were 
dissected. Care was taken to cut the pituitary stalk, and the pituitary with the 
remaining stalk were then dissected free of the sella turcica on the base of the 
skull. The pituitary gland was taken and immediately stored at –80°C; cDNA was 
prepared as described in (2.3.10.3). Popliteal lymph nodes (LNs) draining the 
CFA-treated rat hind paw or in case of untreated animals, popliteal and inguinal 
LNs from both sides were dissected. Embedded fat tissue around the LN was 
thoroughly removed using scalpels. The tissue was homogenized using sterile 
plastic pestles and blades. Cells were dissociated from homogenates using 70 µm 
and 40 µm mesh cell strainers and suspended in sterile-filtered 1x phosphate 
buffered saline (PBS) or RPMI-1640 medium. In parallel to cell counting, the cell 
viability was examined via the trypan blue exclusion method using Fuchs-
Rosenthal cell counting chambers. Finally, cell suspensions were used for various 
experimental procedures such as magnetic cell sorting (MACS), flow cytometry, 
immunohistochemistry, immunofluorescence, electroporation, RNA-isolation, ex 
vivo stimulation and radioimmunoassay (RIA) or the cells were pelleted for storage 
at –20°C for subsequent RIA or PCR analysis. 
2.2.4 Magnetic cell sorting (MACS) 
Freshly isolated rat and mouse cells as described in (2.3.3.) were centrifuged 
for 10 min at 450 × g at room temperature and then resuspended in 1 ml of RPMI 
medium-1640 medium (+Glutamax I). Then 20 µl/107 cells of (1) anti-rat CD8, (2) 
anti-rat CD45RA, (3) anti-rat CD4, (4) anti-mouse CD45, or (5) anti-rat MHC class 
II (OX6) microbeads were added to isolate cell subsets from the cell suspensions. 
Samples were incubated for 15 min at 6 °C sitting on a slow rotor socket. 
Thereafter, cells were washed twice in RPMI medium to remove unbound beads. 
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Labelled cell suspensions were loaded onto separation columns placed in a 
magnetic field according to the manufacturers' instructions. Unlabelled cells 
passing the magnetic field were collected as negative fractions (e.g. CD8-, 
CD45RA- etc.). To collect the labelled cells, the columns were removed from the 
magnetic field and rinsed with RPMI medium under high pressure. The labelled 
cells were collected as positive fractions (e.g. CD8+ or CD45RA+). Fractions were 
then centrifuged for 5 min at 4 °C and 350 × g. Supernatants were removed and 
cell pellets were resuspended in PBS for cell counting. Separated cells were 
subjected to release or cell stimulation experiments or they were used for 
gene/protein expression analysis (PCR, RIA, immunohistochemistry). 
2.2.5 Rat LN cell experiments 
2.2.5.1 Stimulation of total LN cells 
Unseparated LN cells (1 - 2 x 107 cells/well) were loaded on 6-well plates and 
serum-free RPMI-1640 medium supplemented with 1% penicillin/streptomycin was 
added to a final volume of 3 ml/well. IL-2 (20 ng/ml), IL-4 (10 ng/ml), IL-5 (25 
ng/ml), IL-6 (10 ng/ml), IL6-Rα (100 ng/ml), IL-10 (50 ng/ml), Leptin (10 ng/ml), 
and leukaemia inhibitory factor (LIF, 10 ng/ml) and/or the mitogen concanavalin A 
(ConA, 1 µg/ml) were added to the culture medium. Cells were subsequently 
incubated for 2 - 24 h at 37°C and 5% CO2. Control cells were incubated without 
stimulating agent. 
2.2.5.1.1 Treatment with methyltransferase and histone deacetylase 
inhibitors 
A DNA methyltransferase inhibitor was used to study the effect of methylation 
on POMC  gene expression, based on (Brueckner et al., 2005).  2-(1,3-Dioxo-1,3-
dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid (RG108) is a small 
molecule that effectively blocked DNA methyltransferases in vitro in human cancer 
cell lines (B cells: NALM-6, colon: HCT116). We supplemented media with 10% 
fetal bovine serum and RG108 to a final concentration of 10 µM, and primary 
naïve LN-derived cells were harvested after 7, 10, and 15 days followed by RNA 
isolation, cDNA synthesis and qRT-PCR analysis for POMC gene expression. The 
serum-containing medium and RG108 were refreshed ev
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The histone deacetylase inhibitor trichostatin A interferes with deacetylation and 
produces an accumulation of acetylated histones, which is expected to enhance 
transcription. A final concentration of 1 µM trichostatin A was applied for 24 to 120 
h followed by RNA isolation, cDNA synthesis and qRT-PCR analysis for Pomc 
gene expression. 
2.2.5.2 Stimulation of LN cell subsets and T cell supernatant transfer 
experiments 
Magnetically separated T and B cells (1 - 2 x 107 cells/well) were loaded onto 
different 6-well plates and serum-free RPMI-1640 medium supplemented with 1% 
penicillin/streptomycin was added to a final volume of 3 ml/well. Different cytokines 
and/or inhibitors were added to the culture medium RPMI. 
2.2.5.2.1 Cytokine stimulation and inhibitor treatment of lymphocytes 
Naïve lymphocytes were incubated with microbeads (CD45RA, MHC class II 
from Miltenyi Biotech) and separated into T and B cells using MACS separation 
columns. B cells were unstimulated; T cells were pre-treated with cell-permeable 
small molecule inhibitors (Calbiochem, EMD Chemicals Inc., Darmstadt, Germany) 
prior to the addition of IL-4. Pyridon 6 (a pan-JAK inhibitor) and STAT-5 inhibitor 
were added at concentrations of  0.3, 0.6 and 1 µM for 30 min. 2 h after the 
addition of IL-4 (10 ng/ml), the supernatants from T cells were collected and 
transferred to untouched B cells. After B cell stimulation for 2 h at 37 °C, cells were 
collected on ice, centrifuged and pellets were stored at −80 °C. (Fig. 2.1) depicts a 
scheme of the experimental procedure. 
 
Figure 2.1 Primary naïve T and B cells were separated from dissociated LN cells using anti-
CD45RA microbeads and MACS columns. T cells were pre-treated for 30 min with/without 
inhibitors prior to the addition of IL-4. Controls were left untreated. After 2 h of IL-4 stimulation, the 
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supernatant from T cells was collected and transferred to untouched B cells. B cells were exposed 
to the T cell supernatants for 2h.  
In a second series of experiments, B cells were pre-treated with cell-
permeable small molecule inhibitors (Calbiochem, EMD Chemicals Inc., 
Darmstadt, Germany). Pyridon 6 and STAT-5 inhibitor were added at final 
concentrations of 0.3, 0.6, and 1 µM each and incubated for 30 min at 37 °C. 
Meanwhile, T cells were stimulated with IL-4 for 2h, and then the supernatant from 
the T cells was collected and transferred to pre-treated B cells. After 2 h of B cell 
stimulation at 37 °C, cells were collected on ice, centrifuged and pellets were 
stored at −80°C. (Fig. 2.2) depicts a scheme of the experimental procedure. 
 
Figure 2.2 Primary naïve T and B cells were separated from dissociated LN cells using anti-
CD45RA microbeads and MACS columns. B cells were pre-treated for 30 min with inhibitors, 
controls were left untouched. T cells were stimulated with IL-4 but not with inhibitors; After 2 h the 
supernatant was transferred to the pre-treated B cells. B cells were exposed to the T cell 
supernatant for 2 h. 
2.2.5.3 Electroporation of rat LN cells for siRNA delivery 
Lymphocytes were isolated from rat LNs as described in (2.3.3), and vital 
cells were treated with hypotonic solution. We chose to deliver siRNA using two 
different electrical devices: one system was developed by a research group at the 
Charité Campus Benjamin Franklin (Thorsten Stroh of the AG Siegmund); the 
other is a commercially available Multiporator system from Eppendorf. The AG 
Siegmund setup can produce high voltage/low duration and low voltage/long 
duration pulses, which can be used as single pulses or can be combined as 
double pulses. The application of a double pulse (1st pulse: 400-500 volts for 100 
microseconds, 2nd pulse: 200 volts for 10 milliseconds) delivered a FITC-tagged 
control siRNA (BLOCKiT, Invitrogen) most efficiently after 24 to 48 h (75% uptake, 
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approx. 50% viability) as monitored using flow cytometry analysis with the help of 
Dr. Rainer Glauben (AG Siegmund, Department of Internal Medicine with 
Gastroenterology and Nephrology, Charité Universitätsmedizin Berlin, Campus 
Benjamin Franklin). The cell number was 2-3 million per sample. The pulse profile 
of the Eppendorf Multiporator does not offer a similar double pulse condition. This 
system instead runs a profile of an exponential voltage drop every 5 microseconds 
(soft pulse technology) in combination with a hypoosmolar electroporation buffer. A 
starting pulse of 600 volt and a time constant of 25 microseconds produced similar 
uptake and viability rates to those obtained with the AG Siegmund setup. The 
electroporated cells were suspended in a medium containing penicillin, 
streptavidin, and FBS (fetal bovine serum) and incubated for different time periods 
ranging from 1 to 7 days. The cells were spun down, and the pellet was used for 
either real-time PCR or western blot. When used for real-time PCR, the samples 
were prepared as described in section (2.2.10) to analyse the mRNA expression. 
2.2.6 Preparation of knee joint cells from ACIA mice and release experiments 
The knees that had received the intraarticular (i.a.) mBSA-injections were 
dissected; the knee capsule was cut into halves. The knees were digested in 3 ml 
RPMI-1640 medium containing 9 mg hyaluronidase and 3 mg collagenase II per 
ml for 45 min at room temperature. The soft tissue surrounding the bones was 
thoroughly removed and ground. The homogenate was transferred into new tubes 
via 70 micron and later through 40 micron sieves and rinsed with enzyme-free 
medium. After spinning for 10 min at 450 x g at room temperature, the supernatant 
was discarded and the cells were resuspended in 1 ml culture medium and 
incubated with 25 µl anti-mouse CD45 micro beads for 15 min at 4 ºC in a rotor. 
Samples were spun down again at 2,000 rpm for 10 min at 4 ºC to remove 
unbound beads. The supernatant was discarded, and the pellets were 
resuspended in 1 ml medium. Cells were counted and resuspended in 250 µl pure 
medium and kept for 2 h at 37 ºC under agitation (350 rpm). Later the tubes were 
spun down (2,000 rpm for 10 min) at 4 ºC and supernatants and pellets were 
stored at –80ºC for further analysis of opioid peptide release and cellular content, 
respectively, using RIA. 
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2.2.7 Radioimmunoassay (RIA), enzyme immunoassay (EIA) and cytokine 
array 
Immunoreactive Met-enkephalin (ir-MENK) was determined using a RIA kit. 
All substances were dissolved in 1 × RIA buffer. Mouse knee cells were isolated as 
described in 2.2.6. Whole cell lysates were prepared from frozen cell pellets via 
freeze-and-thaw lysis in 200 µl RIA buffer. Freezing and thawing was repeated five 
times: first, samples were kept for 5 min in liquid nitrogen; they were then quickly 
thawed in a water bath (22 °C) and briefly vortexed. After a final incubation of 10 
min on ice, the samples were centrifuged for 10 min at 27,000 × g and 4 °C to 
remove debris. Clear cell lysates (100 µl each) were used for measurements 
thereafter. Supernatants (100 µl each) from release experiments as detailed above 
(2.2.6), were directly used for RIA measurements without further processing steps. 
All samples were prepared in duplicate. Serial diluted MENK standards containing 
1-1,280 pg MENK / 100 µl RIA lysis buffer were prepared in parallel using a 
standard peptide supplied by the company. Then, antiserum (100 µl) was added to 
all tubes except the total count, non-specific binding, and total binding tubes. 
According to the manufacturers' specifications, the rabbit anti-MENK does not 
cross-react with other agents such as Dynorphin, β-Endorphin, or ACTH. Tubes 
were incubated for 16-24 h at 4 °C. Then 100 µl 125I-labeled MENK with 11,000-
15,000 counts per minute (CPM) was added to each tube, and tubes were left for 
another 16-24 h at 4 °C. Thereafter, 100 µl each of goat anti-rabbit IgG and normal 
rabbit serum were added to all samples in order to precipitate antibody-protein 
complexes. The reaction was stopped after 90-120 min at room temperature by 
adding 0.5 ml RIA buffer. Finally, tubes were spun at 3,000 rpm for 20 min at 4 °C. 
Supernatants were aspirated of all except total count tubes, and the radioactivity in 
the pellets was counted as CPM in a gamma-counter. To determine specific 
binding, the mean CPM of non-specific binding samples was subtracted from all 
other samples. The CPM thereby decreases with an increasing peptide 
concentration of the unknown samples or standard peptide. The amount of ir-
MENK was calculated in pg/well. 
 The β-endorphin-immunoreactivity (ir-END) was determined using an END 
enzyme immunoassay (EIA). The remaining supernatants (approximately 50 µl 
each) from release experiments as described in (2.2.6), were directly used for EIA 
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measurements without further processing steps. The release of END was 
determined in cell supernatants using a human/rat-fluorescent EIA kit according to 
the manufacturers' instructions (Phoenix Peptides Inc.). Wells of EIA plates were 
loaded with 25 µl of the supernatants per well and incubated overnight at 4 ºC. 
Then 25 µl of biotinylated peptide was added and incubated at room temperature 
for 1.5 h, and the plates were washed with the buffer three times before adding 
100 µl SA-HRP (streptavidin-horseradish peroxidise) solution for 1 h. The plate 
was washed three times and incubated with 100 µl substrate solution at room 
temperature for 20 min. The reaction was terminated by stop solution. The 
fluorescence intensity was measured with a plate reader. The amount of ir-END 
was assessed in duplicate and calculated in pg/well from the standard curve. 
 Cytokine release was analysed using RayBio Rat Cytokine Antibody Array 2 
kits (RayBiotech, Inc., Norcross, GA, USA) following the manufacturers’ 
instructions. Array membranes carrying antibodies for the detection of 34 cytokines 
and anti-rat IgG (loading control) were incubated with T cell supernatants for 2 h. 
After washing, the membranes were incubated for 2 h with a mixture of biotin-
conjugated antibodies, followed by peroxidase-conjugated streptavidin. 
Immunoreactive dots were subsequently visualized using an enhanced 
chemiluminescence (ECL) system, and membranes were exposed to 
autoradiograph hyperfilms for 10 to 40 seconds. Films were scanned and pictures 
were analysed using Image J. After inverting the pictures, the background signal 
was measured at the negative control spots of the blot using an area of fixed size. 
This background signal was subtracted from all other measurements. The signal of 
each antibody spot was determined and recorded as ‘intensity’.  
2.2.8 Cytospins 
Cells were counted using Fuchs-Rosenthal cell counting chambers and cell 
viability was examined with the trypan blue exclusion method. 1.5 million cells 
were taken for cytospin in a volume of 100-200 µl of PBS. Before plating the cells, 
slides were cleaned to remove any greasy stains. A filter paper and a cuvette were 
placed on the slide. To the cuvette 300 µl of 1 x phosphate-buffered saline (PBS) 
were added before spinning at 300 rpm so that the filter paper was wet and did not 
absorb the cells. Next, 100 to 200 µl of cell suspension containing approximately 
1.5 million cells were loaded into the cuvette followed by another spinning at 
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300rpm to gently plate the cells onto the slide. Once the cells were plated, the 
slides were used for immunofluorescence stainings. 
2.2.9 Immunofluorescence stainings 
Cells that were plated on slides were dried and then fixed with 4% PFA and 
4% sucrose for 30 min at room temperature and washed three times with PBS for 
10 min each. Non-specific binding was prevented by incubating the slides for 30 
min at room temperature or overnight at 4 °C in blocking buffer (0.1 M PBS, 0.3% 
Triton X-100, 1% BSA, 4% goat or donkey serum). The slides were then incubated 
overnight at 4 °C or for 2 h at 37 °C with primary antibodies (anti-PC1, anti-PC2, 
anti-END, anti-MENK, anti-Dicer). Unbound antibody was removed by washing 
three times with PBS for 10 min each. Incubation with the secondary antibody was 
performed for 1 h at 37 °C followed by three washes with PBS. The slides were 
dried, and the cover slips were sealed with 10 µl of Mowiol. After the Mowiol 
hardened, the slides were imaged using a fluorescence microscope system and 
the AxioVision program (Zeiss Axioskop 2). Image analysis was performed using 
Image J (Version 1.47 developed by the NIH) as follows: 
 At first, fluorescence intensity was measured for the sample incubated with 
the secondary antibody only to determine the background threshold. This 
threshold was subtracted from the fluorescence of all other images. Then the 
number of particles above threshold, their area, and the mean fluorescence was 
determined using the option ‘analyse particles’ in Image J. The size of single cells 
was measured using the circle tool and values of 30 cells were used to obtain a 
mean area. This mean was used to calculate the cell numbers from the total area 
above the threshold determined with the particle analyser. The mean fluorescence 
and cell numbers above threshold were plotted on graphs.  
2.2.10 Gene expression analysis 
2.2.10.1 Total RNA preparations 
Total RNA was prepared using the Total RNA Isolation NucleoSpin RNA II kit 
(Macherey and Nagel) following the manufacturers' protocol. Fresh or frozen cells 
or tissues (pituitary and LN) were homogenized in 4 M guanidine thiocyanate 
buffer containing 10 µl β-mercaptoethanol per ml. Homogenates were loaded onto 
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shredder columns to remove cell debris by spinning samples for 1 min at 11,000 
rpm at room temperature. After adding 70% ethanol to the flow-through, samples 
were immediately mixed and then transferred to silica membranes to bind DNA 
and RNA. The membranes were desalted using membrane desalting buffer 
(MDB). To remove DNA, membranes were treated with RNase-free DNase for 15 
min. Subsequently, membranes were washed with wash buffers provided by the 
kit. Total RNA was eluted in 30-40 µl RNase free ddH2O and stored at –80°C. RNA 
was isolated from LN or pituitary tissue on separate days to avoid contamination. 
2.2.10.2 RNA/DNA quantification and quality 
The amount of single-stranded RNA or double-stranded DNA was measured 
photometrically at a wavelength of λ = 260 nm. An A260 nm = 1 corresponds to a 
concentration of 40 µg RNA/ml or 50 µg DNA/ml. The quality of RNA and purity of 
DNA was verified by A260 nm/A280 nm ratios. This ratio lies between 1.5 and 1.9 for 
intact RNA and between 1.75 and 2.0 for DNA. 
2.2.10.3 First-strand synthesis and negative controls  
Total RNA (1 - 2.5 µg/15.6 µl) was reverse-transcribed in 26 µl reaction 
mixture containing 0.2 µg/ml primer oligo dT, heated for 3 min at 63 °C and 
subsequently chilled on ice. Then the following reagents were added to a final 
volume of 30 - 40 µl: 1 × RT reaction buffer (50 mM Tris HCl, pH 8.3; 75 mM KCl, 
3 mM MgCl2), 10 µM dithiothreitol (DTT), 1 µM deoxynucleotide triphosphate mix 
(dNTP), 1 U RNAse inhibitor and 6 U AMV reverse transcriptase (RT). For 
negative controls, RT was replaced by RNase-free H2O (RT-). Mixtures were 
incubated for 120 min at 42 °C. cDNA was stored at –20°C thereafter. 
 
2.2.10.4 PCR primers 
 
 Oligodeoxynucleotides were designed by applying the OLIGO Primer 
Analysis Software Version 5.0 for Windows (Wojciech Rychlik, National 
Biosciences, Inc., Plymouth, MN) and were purchased from TIBMOLBIOL (Berlin, 
Germany). Primer pairs designed for the amplification of β-actin, PC1, PC2, 
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Cathepsin-L, Aminopeptidase B, Pomc, Sfrp1, Dicer, and IL-10,   were exon-intron 
spanning.  
2.2.10.5 Real-time quantitative reverse-transcription PCR (qRT-PCR) analysis 
Quantitative real-time PCR was performed using the FastStart DNA Master 
PLUS SYBR Green 1 kit according to the manufacturers' instructions (Roche). 
Real-time PCR was performed using the Mastercycler ep realplex (Eppendorf). 
The final reaction volume of 20 µl contained 25 pM antisense primer, 25 pM sense 
primer, 1 × PCR buffer with 2.0 mM MgCl2, 0.8 mM dNTPs, 1U AMV polymerase 
and either 2 µl template or RT- control. Positive controls contained 2 µl pituitary (P) 
or placenta (PL) cDNA; negative controls (NC) were supplemented with 2 µl 
ddH2O. Each assay started with an initial denaturation cycle of 10 min at 95 °C, 
followed by 40-45 amplification cycles (8 sec/95 °C denaturation, 8 sec/55-68 °C 
annealing, and 8-20 sec/72 °C for extension). Detailed PCR conditions for Pomc, 
Dicer, PC1, PC2, Sfrp1, and β-actin mRNA are listed in table 2.8. 
Table 2.8 RT-PCR conditions for different gene transcripts 
 
Gene AT (annealing 
temperature) ºC / sec 
Elongation  TM (melting 
temperature) 
Fragment 
size 
β-Actin 68 72 ºC / 10 85 191 
POMC 63 72 ºC / 27 89 668 
PC1 55 72 ºC / 10 82 254 
PC2 69 72 ºC / 10 87 207 
Cathepsin L 62 72 ºC / 13 83 312 
Aminopeptidase B 62 72 ºC / 13 85 312 
Dicer 67 72 ºC / 11 82 251 
IL-10 60 72 ºC / 10 86 241 
Sfrp1 60 72 ºC / 20 91 492 
Data were analysed using the master cycler software (Eppendorf, Hamburg, 
Germany). The excess of background emission by specific amplification was 
automatically determined as a crossing point (CP). The relative expression of 
target mRNAs was evaluated in treated vs. control conditions and relative to the 
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expression of β-Actin as housekeeping gene by applying the delta-delta CP 
method previously described by PE Applied Biosystems (Perkin Elmer, Foster 
City, CA). Samples were always analysed as a set that was amplified together in 
the same qRT-PCR run. The 'relative expression ratio' of target mRNAs was 
calculated following the equations previously described by de Longueville and 
colleagues (2003): 
∆CP = CPPOMC – CPActin 
∆∆CP = ∆CP treated - ∆CP control 
Relative expression ratio = 2 –∆∆CP 
2.2.10.6 Melting curve analysis 
Subsequent to amplification, qRT-PCR products were heated from 65 °C to 
95-99 °C using a temperature transition rate of 0.1 °C / sec following the 
manufacturers' instructions. The level of fluorescence (F) was measured 
continuously during heating, changing relative to (1) the presence or absence of 
PCR products and (2) to the temperature (T). Melting curves – providing 
information about product specificity – were automatically calculated by the 
Eppendorf system and plotted as the ratio of changes of fluorescence to 
temperature changes [-∆F1/ ∆T] over temperature. Curves obtained from pituitary 
material were used as a positive control to evaluate LN-derived qRT-PCR products 
with the exception of Sfrp1 expression, which is not expressed in the pituitary. 
Control cDNA was used from placenta instead. Products were cooled down to 4 °C 
thereafter. 
2.2.10.7 Agarose gel electrophoresis 
Electrophoresis was run at 110 volts constantly for 40 min in 1 x TBE buffer 
(100 mM Tris base, 100 mM boric acid, 2.5 mM EDTA). Therefore, 20-25 µl PCR 
products were mixed with 4-5 µl agarose gel sample buffer (0.25% bromphenol 
blue, 50 mM Tris pH 7.6, 60% glycerol, H2O) and transferred to 1% agarose gels 
(1 x TBE, 1% agarose, 1 µl Midori green or 4 µl Midori green advanced/100ml). 
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 A 100 bp DNA ladder (Roche, Germany) was run in parallel to estimate sizes 
of PCR products. PCR products were imaged with a Biorad documentation 
system. 
2.2.11 Bisulfite sequencing 
2.2.11.1 Bisulfite modification 
Bisulfite modification of DNA occurs in three steps including sulphonation, 
deamination and desulphonation (Hayatsu et al., 1976; Shapiro et al., 1973; 
Shapiro et al., 1970). After these processes all unmethylated cytosine bases are 
converted into uracil, while methylated cytosine bases do not change. During PCR 
amplification uracil bases are replaced by thymine (Roux et al., 1995). This allows 
methylated cytosines to be distinguished from unmethylated cytosines during 
downstream analysis. 
2.2.11.2 Process of bisufite modification 
An EZ DNA methylation kit was used for bisulphite modification. The protocol 
used followed the manufacturers' instructions without modifications. According to 
this protocol, 5 µl of M-dilution buffer was added to genomic DNA (1 µg). The total 
reaction volume was 50 µl in each tube with nanopure water. Solutions were 
mixed by pipetting up and down. Sample tubes were incubated at 37 ˚C for 15 min 
in a PCR thermal cycler. After incubation, 100 µl freshly prepared CT conversion 
reagent was added to each tube and mixed well. These sample tubes were kept in 
a PCR machine and 20 PCR cycles were programmed. Each cycle consisted of 
95˚C for 30 seconds and 50 ˚C for 15 min. Following cycling, the samples were 
cooled to 6 ˚C. They were then added to 400 µl of M-binding buffer in Zymo-
Spin™ IC columns and these columns were placed into collection tubes. The 
solutions were mixed by gently pipetting up and down. The columns with collection 
tubes were centrifuged at >10,000 x g for 1 min. Flow-through was discarded after 
every centrifuge step unless otherwise stated. 200 µl M-wash buffer was added to 
each column and centrifuged at full speed for 1 minute. 200 µl M-desulphonation 
buffer was added to the columns and left at room temperature (20 ˚C to 30 ˚C) for 
15 min in the dark. The columns were centrifuged at full speed for 1 min. 200 µl M-
wash buffer was added and centrifuged at full speed for 1 min. This step was 
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repeated, followed by another centrifugation for 2 min. Then the columns were 
placed into 1.5 ml microcentrifuge tubes and 10 µl dH2O was added. The tubes 
were centrifuged for 1 min at full speed, and bisulphite-modified DNA was eluted. 
Bisulphite-modified DNA is not stable and has to be stored at –80 °C. 
2.2.11.3 PCR conditions 
Usually we used 35 to 45 cycles for successful PCR amplification of bisulfite-
converted DNA. The protocol includes 5-10 cycles for priming, followed by 35 to 40 
amplification cycles. Annealing temperatures were 50-70°C. UTR primers were 
designed for the untranslated regions of the sequence. C-free primers were 
designed to bind to both the untranslated and bisulfite-converted sequences, as 
they are independent of cytosine residues. Bisulfite-specific primers (BSP) were 
designed to amplify converted DNA. Different BSP primers were designed to 
amplify regions with different product sizes and nested BSP primers were also 
designed. Methylation-specific primers (MSP) bind specifically to methylated sites 
that could virtually appear at any CpG sites in a CpG island, but those primers 
were also based on the converted DNA sequence. We designed such primers to 
distinguish methylated from unmethylated sites of the Pomc locus, taking 
advantage of the sequence differences resulting from bisulphite modification. MSP 
primers were designed using the methyl primer express design tool from Applied 
Biosystems. 
Table 2.9 List of UTR and C-free primers – sequences, length and PCR conditions are given 
Name Sequence (5`- to -3`) bp Tm (°C) 5 
cycles / 
40 cycles 
Primer type 
UTRrPOMCse1(234) CTGCCTTGGGCTGCCATGATTCT 23 65/70 sense 
UTRrPOMCse2 (235) CTCTGTCCAGTCCTGAGTGGAG 22 65/70 sense 
UTRrPOMCas (236) GGTTAAGGAGCAGTGACTAAGAGAGGC 27 65/70 antisense 
C-free POMC FW TTGGAATAAGTATTGGGGATGGAGA 25 55/65 sense 
C-free POMC RV1 GGAGGAGAAAAGAGGTTAAGGAG 23 55/65 antisense 
C-free POMC RV2 AGGTATAAAAGAAGAGAGAAGAGTGA 26 55/65 antisense 
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Table 2.10 List of BSP primers – sequences, length, and PCR conditions are given 
Name Sequence (5`- to -3`) bp Tm (°C) 5 
cycles / 
40 cycles 
Primer type 
BSP (FW) 116 TTGTTTTGGGTTGTTATGATTTT 23 55/65 sense 
BSP (FW) 118 AGGTAGTTTGTTTTGGGTTGTT 22 55/65 sense 
BSP (FW) 120 TTTTGTTTAGTTTTGAGTGGAG 22 55/65 sense 
BSP (RV) 117, 119, 
121 
GGTTAAGGAGTAGTGATTAAGAGAGGT 27 55/65 antisense 
 
Table 2.11 List of MSP primers – sequences, length, and PCR conditions are given 
Name Sequence (5`- to -3`) bp Tm (°C) 5 cycles 
/ 40 cycles 
Primer type 
MSP_1_FW 261 TAATATTGGGGAAATTTGATGT 22 50/62 sense 
MSP_1_RV 801 AACCAAAACACCCTTACCTATC 22 50/62 antisense 
MSP_2_FW 199 TGTTGTTTTTTTTTTTGAAAT 21 50/62 sense 
MSP_2_RV 621 CCTTCCTAACAACACTTCTAC 21 50/62 antisense 
MSP_3_FW 261 TATTGGGGAAATTTGATGC 19 50/62 sense 
MSP_3_RV 801 AACCGAAACACCCTTACCTA 20 50/62 antisense 
MSP_4_FW 199 GTTGTTTTTTTTTTCGAAAC 20 50/62 sense 
MSP_4_RV 621 CTTCCTAACAACGCTTCTAC 20 50/62 antisense 
2.2.11.4 Purification of PCR products via gel extraction 
After electrophoretic separation, PCR product bands were cut out, and DNA 
was extracted from the gel by using the QIAGEN gel extraction kit according to the 
manufacturers' instructions. DNA was eluted in 30-40 µl H2O and was sent for 
sequence analysis to LGC Genomics GmbH (Berlin, Germany). 
2.2.12 Immunohistochemistry (IHC) of arthritic mouse knees 
Animals were killed and both knee joints were fixed in 4% buffered 
formaldehyde, decalcified with EDTA, and embedded in paraffin. Serial sections 
(4–5 µm thick) were cut and stained with haematoxylin eosin (HE) for microscopic 
evaluation. Dr. Uta Baddack scored the knee sections in a blinded manner, 
examining three sections per knee joint. A three parameter scoring system was 
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used, where individual scores comprise the following: acute score (exudate: 1–3 
points, granulocytes infiltrating the synovial membrane: 1–3 points, fibrin exudates: 
1 point), chronic score (synovial hyperplasia: 1–3 points, mononuclear cells 
infiltrating the synovial membrane: 1–3 points, fibrosis: 1–3 points), cartilage and 
bone destruction (1–3 points). 
For immunohistochemistry, paraffin sections were deparaffinised using xylol 
acetone and unmasked by heat. For staining, the following primary antibodies 
were used: anti-CD3e (goat, Santa Cruz Biotechnology, Santa Cruz, CA), anti-β-
endorphin (Bachem Group, Peninsula Laboratories, UK). For detection, 
biotinylated donkey anti-goat, donkey anti-rat or peroxidase-coupled donkey anti-
goat antibodies were added, followed by streptavidin-conjugated alkaline 
phosphatase (all from Jackson ImmunoResearch, Newmarket, UK). Enzyme 
reactions were developed with AECþSubstrate Kit (DAKO) or Fast Blue substrate 
(Sigma-Aldrich). 
2.2.13 Statistical analysis 
All data were processed using Microsoft Excel 2003 for Windows (Microsoft 
Corporation) and GraphPad Prism Version 5.01 for Windows (GraphPad Software, 
Inc.). GraphPad Prism was used for the statistical analysis. Data were analysed for 
equal variance and for normal distribution using the D'Agostino & Pearson 
omnibus normality test. Normally distributed data were analysed by Student t-test 
and nonparametric data by Mann-Whitney-U-Test if two independent groups were 
compared. In case of dependent data, the paired t-test and the Wilcoxon signed 
rank test were used to analyse normally distributed and non-parametric data, 
respectively. Multiple measurements of normally distributed, independent data 
were analysed with the One-Way ANOVA test or the Kruskal-Wallis test in case of 
not normally distributed data. Dependent data were analysed using the One-Way 
Repeated Measurers ANOVA or the Friedman test to compare more than two 
groups with a normal or non-parametric distribution, respectively. Post hoc 
comparisons were performed with Dunnett’s multiple comparison test for normally 
distributed data and with Dunn’s method for not normally distributed data. For all 
tests, statistical significance was considered if P < 0.05. Data represent the mean 
± the standard error of the mean (SEM). 
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3 Results 
3.1 Regulation of pro-opiomelanocortin (Pomc) mRNA expression 
 Full-length Pomc mRNA is difficult to detect in naïve lymphocytes. Therefore 
we hypothesized that it may be repressed under unstimulated conditions. We studied 
different mechanisms that may either interfere with Pomc gene expression or 
strengthen the degradation of Pomc mRNA. 
3.1.1 Possible repressive mechanisms regulating Pomc mRNA expression in 
lymphocytes 
3.1.1.1 Repression by methylation or acetylation 
 To investigate the possible role of DNA methylation in the expression of Pomc, 
primary naïve LN cells were treated in vitro with IL-4 in order to stimulate Pomc 
expression as previously described (Busch-Dienstfertig et al, 2012) or were left 
untreated (see section 2.2.5.1), and genomic DNA was isolated from separated T 
and B cells thereafter. DNA strands were subjected to bisulfite treatment (see section 
2.2.11), which normally results in the conversion of unmethylated cytosines (C) into 
uracils (U) while methylated cytosines remain unaffected. A sequence of 
approximately 700 bp in total, comprising the 5`-upstream untranslated region (UTR) 
and exon 1 of the Pomc gene, was amplified using RT-PCR and different primer 
combinations (see section 2.2.11.3). Before bisulfite conversion, the DNA strands 
were amplified using UTR primers to test the integrity of the Pomc locus and were 
inspected electrophoretically. The PCR products generated from bisulfite converted 
DNA strands were also separated via agarose gel electrophoresis (see section 
2.2.10.7), selected by size, and directly sequenced to screen for cytosine 
replacements by uracil. Sequence analyses after bisulfite treatment showed no clear 
peaks, which indicates that either nucleotides were unreadable or nucleotides were 
not successfully converted and were identical to unconverted genomic DNA. 
Therefore, the results were inconclusive. 
 Next, we tried to address the question about DNA methylation by using DNA 
methyltransferase inhibitors based on the paper by Brueckner and colleagues (2005). 
The authors used 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-
yl)propionic acid (RG108), a small molecule that was shown to effectively block DNA 
methyltransferases in vitro in human cancer cell lines. We supplemented media with 
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RG108 and kept primary LN-derived cells from healthy animals in culture. The 
inhibitor was added at a final concentration of 10 µM, and cells were harvested after 
5, 10, and 15 days followed by RT-PCR analysis (see section 2.2.10.5). β-Actin 
levels confirming the quality of cDNA and RT PCR are given in (Fig. 3.1 A). As a 
positive control, we amplified Sfrp1 mRNA. The Sfrp1 gene is known to be 
suppressed by methylation and upregulated upon RG108 treatment in HCT116 cells 
(HCT 116 Cell Line human colon carcinoma). Sfrp1 mRNA was not expressed in 
untreated LN cells but was detectable in RG108-treated LN cells after 15 days (Fig. 
3.1 B). No Pomc mRNA expression was detected in untreated or RG108-treated cells 
at the time points investigated (Fig. 3.1 C). Together, these results suggest that 
Pomc mRNA is not expressed after DNA demethylation in these cells. 
 
Figure 3.1 Effect of RG108 on Pomc and Sfrp1 gene expression in lymphocytes Unseparated 
primary, naïve LN-derived cells were treated with 10 µM RG108, harvested after 15 days, and 
followed by RNA isolation, cDNA synthesis, and PCR. Number of independent experiments: n = 6.  A 
shows the expression of β-actin; pituitary cDNA served as positive control. B shows Sfrp1 mRNA 
expression; placenta cDNA served as positive control. C shows Pomc gene expression (Pomc mRNA 
transcripts); pituitary cDNA served as positive control. All PCR products were electrophoretically 
separated by size by using agarose gel electrophoresis. A DNA marker (M) was run in parallel to 
estimate the product size. NC = water control. Control = untreated cells kept under otherwise identical 
conditions.  
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 A reduced transcriptional activity can also be related to the deacetylation of 
histones, which increases the affinity of histone proteins to DNA. The histone 
deacetylase inhibitor trichostatin A produces an accumulation of acetylated histones, 
which is expected to enhance transcription by decreasing the histones’ affinity to 
DNA. However, treatment of lymph node cells with 1 µM trichostatin A for 24 h did 
not increase Pomc gene expression (Fig. 3.2 A). β-Actin was used as an internal 
control (housekeeping gene) to confirm cDNA quality and RT-PCR efficacy. 
 
Figure 3.2 Effect of trichostatin A on Pomc gene expression in lymphocytes Unseparated 
primary, naïve LN-derived cells were treated with 1 µM of trichostatin A, harvested after 24 h, followed 
by RNA isolation, cDNA synthesis, and PCR. Number of independently performed experiments: n = 4. 
PCR products were electrophoretically separated by size using agarose gel electrophoresis. A: Pomc 
gene expression (Pomc mRNA transcripts). B: β-actin expression. Pituitary cDNA served as positive 
control. M = DNA marker. Control = untreated cells kept under otherwise identical conditions. 
 Finally, cells were treated with both 10 µM RG108 and 1 µM trichostatin A. 
The cells were incubated in the presence of RG108 for 5, 10, and 15 days as in the 
previous experiments, and trichostatin A was added on the 4th, 9th, and 14th day (24 h 
before harvesting the cells). Sfrp1 expression was observed only in the cells treated 
with RG108 and trichostatin A (Fig. 3.3 A), confirming that Sfrp1 expression is 
suppressed by DNA methylation. β-Actin expression attested to the RT efficiency and 
cDNA quality of the samples (Fig. 3.3 B). No increase in Pomc gene expression was 
detectable in treated versus untreated cells (Fig. 3.3 C). Together these results 
indicate that Pomc gene repression in lymphocytes is not diminished by 
demethylation or increased acetylation. 
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Figure 3.3 Effect of combined RG108 and trichostatin A treatment on Pomc and Sfrp1 gene 
expression in lymphocytes Unseparated primary, naïve LN-derived cells were treated with 10 µM of 
RG108, harvested after 5, 10, and 15 days. Only the 15 day treatment is shown. Moreover, cells were 
treated with 1 µM trichostatin A for 24 h prior to harvesting, followed by RNA isolation, cDNA 
synthesis, and PCR. Number of independent experiments: n = 6. A: Sfrp1 mRNA expression; placenta 
cDNA served as positive control. B: β-actin mRNA amplicons. C: Pomc mRNA transcripts; pituitary 
cDNA served as positive control. Treated = RG108 + trichostatin A. Control = untreated cells kept 
under otherwise identical conditions. M = DNA marker. NC = water control. 
3.1.1.2 Repression by miRNAs 
 Many genes are post-transcriptionally regulated by miRNAs. To assess the 
relevance of miRNAs for Pomc regulation in lymphocytes, primary naïve LN cells 
were transfected with Dicer siRNAs in vitro and Dicer knockdown was investigated 
using qRT-PCR. We tested different methods of chemical siRNA transfer 
(Lipofectamine 2000, Fugene, etc.) using a fluorescent control siRNA. The uptake 
was investigated using flow cytometry, but no conclusive results were obtained. We 
therefore used electroporation (see section 2.2.5.3), although this approach can be 
accompanied by massive cell death. We chose to deliver siRNA using two different 
electrical devices as described in (section 2.2.5.3). The conditions were optimized for 
the uptake of approximately 80% of the fluorescent control siRNA and for at least 
40% cell viability as determined by flow cytometry using the apoptotic marker 
propidium iodide. A significant Dicer mRNA knockdown was observed after 48 h of 
electroporation using the double-pulse strategy when compared to electroporation 
with non-target (scrambled) siRNA (Fig. 3.4 A). Non-electroporated cells of the same 
animal were always investigated in parallel to determine baseline gene expression. 
As a positive control, we amplified IL10 mRNA, which is known to be regulated upon 
knockdown of Dicer (Sharma et al., 2009). IL-10 mRNA was detectable in non-
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electroporated and scrambled siRNA-pulsed cells but was undetectable in Dicer 
siRNA-pulsed cells (Fig. 3.4 C). Dicer knockdown had no effect on Pomc mRNA 
expression (Fig. 3.4 B). 
 
Figure 3.4 Dicer knockdown using electroporation A: Primary, naïve LN cells were treated with 
100 µl of transfection buffer and 100 µM Dicer or non-target siRNA. Cells were harvested after 24 or 
48 h followed by qRT-PCR analysis. Data were calculated using the delta-delta CP method and 
represent the mean ± SEM fold change in Dicer mRNA levels in relation to treatment with scrambled 
siRNA (these levels were set to 1). Statistical analysis was performed using the Kruskal-Wallis test 
and Dunn’s multiple comparison test. ** P < 0.01 (n = 6). Gel electrophoresis of Pomc mRNA (B) and 
IL-10 mRNA (C) transcripts in electroporated and non-electroporated samples after 48 h. Control = 
unpulsed/non-electroporated cells kept under otherwise identical conditions. 
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 To further examine the effect of Dicer knockdown on Pomc mRNA expression, 
we used soft pulse technology as described (in section 2.2.5.3) and harvested the 
cells after 5, 6, and 7 days of electroporation for analysis via PCR and 
immunocytochemistry. Only the results after 5 d of electroporation are shown (Fig. 
3.5), since cell viability at 6 and 7 days was strongly impaired. (Fig. 3.5 A) shows that 
none of the treatments had any effect on Pomc mRNA expression.(Fig. 3.5 B) shows 
successful knockdown of Dicer mRNA in Dicer siRNA-pulsed cells. (Fig. 3.5 C) 
shows β-actin levels confirming the quality of cDNA and PCR. Control experiments 
showed a loss of IL-10 mRNA expression in Dicer siRNA-pulsed cells (Fig. 3.5 D). 
The knockdown of Dicer protein at day 5 post electroporation is shown in (Fig. 3.6). 
The mean fluorescence intensity per cell was significantly decreased in Dicer siRNA 
electroporated cells as compared to basal levels determined in cells electroporated 
with scrambled siRNA (Fig. 3.6). Together, these results indicate no definite 
relevance of miRNA in the regulation of Pomc mRNA. 
 
Figure 3.5 Effects of Dicer siRNA on mRNA expression of β-actin, Pomc, Dicer, and IL-10 using 
soft pulse technology Primary, naïve LN cells were treated with 100 µl of transfection buffer and 100 
µM Dicer or non-target siRNA. Cells were harvested after 5 days, followed by PCR. A: Pomc mRNA 
transcripts, pituitary cDNA served as positive control. B: Dicer mRNA; pituitary cDNA served as 
positive control. C: β-actin mRNA. D: IL-10 mRNA. A DNA marker was run in parallel to estimate the 
product size. Number of independent experiments n=6 per group. 
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Figure 3.6 Dicer siRNA-induced Dicer protein knockdown using electroporation Primary, naïve 
LN cells were treated with 100 µl transfection buffer and 100 µM Dicer or non-target siRNA. Cells were 
harvested after 5 days. Isolated cells were transferred to object trays after centrifugation for 
immunofluorescence analysis. A: representative anti-Dicer stainings of cytospin preparations after 
treatment with Dicer siRNA and scrambled siRNA. B: mean fluorescence intensity per cell after 
treatment with Dicer siRNA and scrambled siRNA (n = 6 animals per group). Statistical analyses were 
performed using the Wilcoxon signed rank test. * P < 0.05. 
 3.1.2 Expression of Pomc mRNA after cytokine stimulation in subsets of T and 
B lymphocytes. 
 Previous studies indicated that Pomc is not expressed in naïve lymphocytes 
but is expressed upon stimulation. It was shown that Pomc gene expression is 
stimulated by IL-4 in vitro (Busch-Dienstfertig et al., 2012) and is upregulated in the 
draining LN after induction of  complete Freund's adjuvant (CFA) paw inflammation in 
vivo (Sitte et al., 2007). Here we investigated Pomc mRNA expression in separated T 
and B cells of dissociated popliteal LNs dissected 2-4 h after injection of CFA into the 
rat hind paw. (Fig. 3.7), Pomc mRNA transcripts were present in B (CD45RA+) but 
not in T cells (CD45RA-). In vitro IL-4 treatment for 2 h increased Pomc mRNA 
expression in B cells only (data not shown), while both cell populations derived from 
naïve LNs expressed pomc mRNA after 24 h of cytokine stimulation. After 24 h 
exposure to IL-4, B cells showed a significantly stronger relative elevation than T 
cells (Fig. 3.8). 
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Figure 3.7 In vivo expression of Pomc mRNA in T and B cells from rat lymph nodes Popliteal 
LNs were dissected and separated using anti-CD45RA microbeads into T (CD45RA-) and B cells 
(CD45RA+) 2h after induction of hind paw inflammation by an i.pl. CFA injection. Pomc mRNA 
transcripts were analyzed using PCR (n = 6 nodes). β-Actin mRNA transcripts, pituitary cDNA served 
as positive control.  pomc mRNA transcripts, pituitary cDNA served as positive control.  
 
 
Figure 3.8 In vitro expression of Pomc mRNA in IL-4-treated T and B cells Primary, naïve LN cells 
were stimulated in vitro with IL-4 for 24 h and subsequently separated using anti-CD45RA microbeads 
into T (CD45RA-) and B cells (CD45RA+); the target gene expression was normalised to β-actin gene 
expression. Number of independently performed experiments: n = 7. Data were calculated using the 
delta-delta CP method and represent the mean ± SEM fold change. Pairwise comparison was 
performed using the Wilcoxon signed rank test, *p < 0.05. 
3.1.2.1 Signaling pathways and interactions between T and B cells in vitro 
 Previous studies showed that IL-4 induces Pomc mRNA expression in 
lymphocytes, which is partially mediated via the JAK/STAT pathway involving 
tyrosine-phosphorylated STATs 1 and 3 but not STAT 6 or MAP kinases such as 
ERK 2 or p38 (Busch-Dienstfertig et al., 2012). As described in the previous 
paragraph, an upregulation of Pomc mRNA expression was detected in B cells, when 
T and B cells were incubated together for 2 h in the presence of IL-4. However, when 
T and B cells were incubated separately with IL-4, no elevation of Pomc mRNA 
expression was observed (in either T or B cells, data not shown), indicating that 
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interaction between the two cell types is required. Since in vivo activation of LN cells 
following paw inflammation also resulted in Pomc gene expression in B but not in T 
cells (Fig. 3.7), more attention was hereupon directed to B cells. When the 
supernatant of IL-4-treated T cells was transferred to purified B cells, an upregulation 
of Pomc mRNA expression was detectable (Fig. 3.9). Together, these results show 
that B cells express Pomc mRNA in a T cell-dependent manner, which is contrary to 
our initial hypothesis. 
   
Figure 3.9 IL-4–stimulated Pomc mRNA expression in B cells Primary, naïve T and B cells were 
separated from dissociated LN cells using anti-CD45RA microbeads and MACS columns. T cells were 
untreated or pre-treated with IL-4. After 2 h, the supernatant (SN) from T cells was collected and 
transferred to untreated B cells. Number of independently performed experiments: n = 5. B cells were 
harvested 2 h after SN transfer and pellets were processed for the analysis of Pomc mRNA levels. 
Data were calculated using the delta CP method and represent the mean ±SEM Pomc-β-actin mRNA 
levels. Statistical analysis was performed to compare delta CP values determined in untreated B cells 
exposed to the SN of unstimulated versus IL-4-treated T cells using Mann Whitney test. **P < 0.01. 
Lower delta CP values indicate higher Pomc mRNA expression. 
 
 Next we used cell permeable inhibitors to interfere with the JAK/STAT 
pathway activated by IL-4. Pyridon 6 is a pan-JAK inhibitor, whereas JAKII and 
STAT-5 inhibitors are selective. The experiments shown in (Fig. 3.10) demonstrate 
that previously untreated B cells express Pomc mRNA when stimulated with the 
supernatant of IL-4-treated T cells. This effect was inhibited by pre-treatment of T 
cells with pyridon 6 and with STAT-5 inhibitor (Fig. 3.10 A); the JAKII inhibitor had no 
significant effect. Pre-treatment of B cells with pyridon 6 and STAT-5 inhibitor 
resulted in significantly decreased Pomc mRNA levels after adding supernatants 
from T cells treated with IL-4 (Fig. 3.10 B), while pre-treatment of B cells with JAK II 
inhibitor seemed to increase this gene expression.  
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Figure 3.10 Effect of JAK/STAT inhibitors on IL-4–stimulated Pomc mRNA expression in B cells 
Naïve T and B cells were separated from dissociated LN cells using anti-CD45RA microbeads and 
MACS columns. A: T cells were pre-treated for 30 min with/without inhibitors prior to the addition of IL-
4. Controls were left untreated. After 2 h, the supernatant (SN) from the T cells was transferred to 
untreated B cells. Number of independent experiments: n = 5. B: B cells were pre-treated for 30 min 
with inhibitors, controls were left untreated. T cells were stimulated with IL-4 and after 2 h the SN was 
transferred to the pre-treated B cells. Number of independent experiments: n = 5. In both setups B 
cells were harvested 2 h after SN transfer, and pellets were processed for the analysis of Pomc mRNA 
levels. Data were calculated using the delta-delta CP method and represent the mean ± SEM fold 
change of Pomc mRNA expression over levels determined in untreated B cells exposed to the 
supernatant of IL-4-treated T cells that were set to 1. Statistical analysis was performed using 
Friedman test and Dunn’s multiple comparison test. *P < 0.05; **P < 0.01; *** P < 0.001. Inhibitors: P6 
= pyridon 6, JAKII inhibitor, STAT-5 inhibitor. 
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 These findings indicated that IL-4, via JAK/STAT activation, leads to the 
release of a factor from T cells, which in turn mediates Pomc gene expression in B 
cells. The results in (Fig. 3.10 B), indicate that the JAK/STAT pathway mediates this 
Pomc mRNA expression in B cells. To find this factor, cytokine array analyses were 
performed with supernatants of in vivo and in vitro activated T cells. Of 34 analysed 
cytokines, almost all were significantly upregulated in the supernatants of T cells 
derived from inflamed LNs in comparison to naïve T cells from non-inflamed LNs. In 
the supernatants of in vitro IL-4-stimulated T cells, IL-2, IL-4, IL-6, IL-10, ciliary 
neurotrophic factor (CTNF), IL-1β, and IFN-gamma were significantly elevated over 
untreated controls (Fig. 3.11).  
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Figure 3.11 (previous and present page) Cytokine secretion changes in stimulated T cells Naïve 
T and B cells were separated from dissociated LNs using anti-CD45RA microbeads and MACS 
columns. B cells were discarded, and T cells were treated with/without IL-4 for 2 h, harvested, and the 
supernatant was analyzed by cytokine array. Similarly, T and B cells were separated by draining LNs 
of i.pl. CFA-treated animals were isolated (2 h after CFA injection). B cells were discarded and T cells 
were kept in the medium for 2 h at 37 ºC, harvested, and the supernatant was analyzed via cytokine 
array. Control (unstimulated) cells were kept under similar conditions. Number of independent 
experiments: n = 6 per group. Densitometry analyses of the array blots were done. Data represent 
mean ± SEM fold change over levels determined in unstimulated controls. Statistical analyses were 
performed using Kruskal-Wallis test and Dunn’s multiple comparison test. *P < 0.05; **P < 0.01. 
 
 Naïve B cells were then treated for 2 h with the upregulated cytokines as 
identified by the cytokine array and with various combinations of cytokines (IL-2, IL-6, 
IL-6Rα IL-10), but no upregulation of Pomc mRNA expression was observed (Fig. 
3.12). At this point it is still an open question as to what the factor is that is released 
from T cells and stimulates B cells to produce Pomc. 
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Figure 3.12 Effect of cytokine treatments on Pomc mRNA expression in naïve B cells B cells 
were stimulated with IL-2, IL-2 + IL-6 + IL-6Rα, IL-2 + IL-10 and with IL-2 + IL-6 + IL-6Rα + IL-10. After 
2 h cells were centrifuged and pellets were processed for the analysis of Pomc mRNA levels using 
PCR. Number of independently performed experiments: n = 6 per group. 
3.2 POMC-processing enzymes 
3.2.1 Prohormone convertase 1 (PC1) in lymph node cells 
 Next we addressed the post-translational regulation of Pomc by examining the 
presence of PC1 mRNA and protein in popliteal LN cells from rats with and without 
CFA-induced hind paw inflammation. In unseparated cells, PC1 mRNA was 
upregulated within 6 h after i.pl. CFA injection vs. control values (Fig. 3.13).  
 Immunofluorescence analysis of PC1 protein is shown in (Fig. 3.14). The 
mean fluorescence intensity per cell and the number of cells above threshold were 
determined and calculated using Image J as described in (2.2.9). PC1 protein was 
significantly increased within 24 h after the onset of CFA-induced paw inflammation 
when compared to basal levels determined in LNs from healthy rats (Figs. 3.14 B and 
C). No significant differences in comparison to control levels were found at 96 and 
120 h (Fig. 3.14 A-C). To verify antibody specificity, preabsorption experiments with 
recombinant PC1 and PC2 peptides were performed (Figs. 3.14 D-E). Staining the 
LN cells with anti-PC1 after 24 h of paw inflammation demonstrated a significant 
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reduction inmean fluorescence intensity per cell after preabsorption with recombinant 
PC1 but not with PC2 (Fig. 3.14 E).  
  
Figure 3.13 In vivo PC1 mRNA expression in lymph nodes Rats received an i.pl. CFA injection and 
popliteal LNs were harvested after 6, 24, and 96 h and from untreated control rats (0 h). PC1 
transcripts were amplified by qRT-PCR. Data were calculated using the delta-delta CP method and 
represent mean ± SEM fold change of PC1 mRNA over levels determined in cells from naïve LNs 
relative to β-actin expression. Statistical analysis was performed using the Kruskal-Wallis test and 
Dunn’s multiple comparison test. *P < 0.05, n = 12 per group.  
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Figure 3.14 In vivo PC1 expression in lymph node cells Rats received an i.pl. CFA injection and 
popliteal LNs were harvested after 24, 96, and 120 h; control nodes were taken from untreated rats. A 
(previous page): Representative anti-PC1 staining of cytospin preparations at the indicated time 
points (n=6 animals per time point). In B (previous page) the number of PC1-positive cells is 
represented in mean ± SEM. C (previous page): Mean fluorescence intensity per cell ± SEM (n = 6 
per group). D: Preabsorption with PC1 but not with PC2 peptide diminished the staining of anti-PC1. 
E: Mean fluorescence intensity per cell ± SEM (n = 4 per group). Statistical analyses were performed 
using the Kruskal-Wallis test and Dunn’s multiple comparison test (compared to PC1 staining without 
preabsorption). *P < 0.05; **P < 0.01; *** P < 0.001. 
 
 To study the expression of PC1 in the subsets of lymphocytes, popliteal LNs 
were dissected and separated using anti-CD45RA microbeads into T (CD45RA-) and 
B cells (CD45RA+) 24 h after the induction of hind paw inflammation. PC1 mRNA 
transcripts were analysed using PCR. β-Actin transcripts confirming the quality of 
cDNA and RT-PCR are shown in (Fig. 3.15 A). (Fig. 3.15 B) shows that PC1 mRNA 
was below detection limit in separated B and T cells from normal LNs. At 24 h of 
CFA-induced paw inflammation, PC1 transcripts were observed in CD45RA+ (B cells) 
and CD45RA- (T cells) of the draining LNs (Fig. 3.15 B). 
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Figure 3.15 In vivo PC1 mRNA expression in B and T cells Rats received an i.pl. CFA injection; 
popliteal LNs were harvested after 24 h and separated into CD45RA- (T cells) and CD45RA+ (B cells) 
using anti-CD45RA microbeads followed by PCR. A: β-Actin mRNA transcripts, pituitary cDNA served 
as positive control.  B: PC1 mRNA transcripts, pituitary cDNA served as positive control. Nodes from 
healthy rats served as controls (0 h). A DNA marker was run in parallel to estimate the product size in 
bp. Number of independent experiments: n = 6 per group, n = 4 are represented.  
 
 Dissociated LN cells were also separated into CD8+ (cytotoxic T cells) and 
CD8- (mixed B and T helper cells) using anti-CD8a microbeads. β-Actin transcripts 
confirming the quality of cDNA and RT-PCR are shown in (Fig. 3.16 A). At 24 h after 
i.pl. CFA, PC1 mRNA was detected in all CD8-, but not in CD8+ cells from inflamed 
LNs (Fig. 3.16 B). PC1 mRNA was undetectable in CD8+ and CD8- fractions of non-
inflamed LNs.  
  
Figure 3.16 In vivo PC1 mRNA expression in cytotoxic T cells and mixed B and T helper cell 
fractions Rats received an i.pl. CFA injection; popliteal LNs were harvested after 24 h and separated 
into CD8+ (cytotoxic T cells) and CD8- (mix of B- and T-helper cells) fractions using anti-CD8 
microbeads followed by PCR. A: β-Actin mRNA transcripts, pituitary cDNA served as positive control. 
B: PC1 mRNA transcripts, pituitary cDNA served as positive control. Lymph nodes from healthy rats 
served as controls (0 h). A DNA marker was run in parallel to estimate the product size in bp. Number 
of independent experiments: n = 6 per group, n = 4 are represented. 
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3.2.2 Prohormone convertase 2 (PC2) in lymph node cells 
 PC2 mRNA was significantly upregulated in unseparated LN cells at 96 h after 
i.pl. CFA injection in comparison to 6 h (Fig. 3.17).  
  
Figure 3.17 In vivo PC2 mRNA expression in lymph node cells Rats received an i.pl. CFA injection 
and popliteal LNs were harvested after 6, 24, and 96 h and from untreated control rats (0 h). PC2 
transcripts were amplified by qRT-PCR. Data were calculated using the delta-delta CP method and 
represent mean ± SEM fold change of PC2 mRNA over levels determined in cells from naïve LNs 
relative to β-actin mRNA expression. Statistical analysis was performed using the Kruskal-Wallis test 
and Dunn’s multiple comparison test. *P < 0.05, n = 8-10 per group. 
 
 Immunofluorescence analysis of PC2 protein is shown in (Fig. 3.18 A). The 
mean fluorescence intensity per cell and the number of cells above threshold were 
determined and calculated using Image J as described in (section 2.2.9). PC2 protein 
was significantly increased within 24 h after the onset of CFA-induced paw 
inflammation when compared to basal levels determined in LNs from healthy rats. No 
significant differences in comparison to control levels were found at 96 and 120 h 
(Fig. 3.18 B).  
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Figure 3.18 In vivo PC2 expression in lymph node cells draining healthily and CFA-inflamed 
hind paws of rats Rats received an i.pl. CFA injection and popliteal LNs were harvested after 24, 96, 
and 120 h; control nodes were dissected from untreated rats. A: Representative anti-PC2 stainings of 
LN cells. B: Mean number of cells above threshold ± SEM (left) and mean fluorescence intensity ± 
SEM (right) of anti-PC2 stained cells are shown. Number of independently performed experiments: n = 
6 per group. Statistical analysis was performed using the Kruskal-Wallis test and Dunn’s multiple 
comparison test (comparison against basal levels). *P < 0.05. 
 
 To verify antibody specificity, the PC2 antibody was preabsorbed with 
recombinant PC1 and PC2 peptides. Staining LN cells at 24 h after CFA injection 
demonstrated a significant reduction of the mean fluorescence intensity per cell in the 
presence of PC2 but not of PC1 peptide in comparison to controls (Fig. 3.19). 
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Figure 3.19 Preabsorption experiments with anti-PC2  A: preabsorption with PC2 peptide 
diminished the staining of anti-PC2; staining was unaffected by preabsorption with PC1 peptide. B: 
Mean fluorescence intensity per cell represented in ± SEM. n = 6. Statistical analyses were performed 
using the Kruskal-Wallis test and Dunn’s multiple comparison test. *P < 0.05. 
 
 To study the expression of PC2 in the subsets of lymphocytes, popliteal LNs 
were dissected and separated using anti-CD45RA microbeads into T (CD45RA-) and 
B cells (CD45RA+) at 24 h after induction of hind paw inflammation. PC2 mRNA 
transcripts were analysed using PCR. β-Actin transcripts confirming the quality of 
cDNA and RT-PCR are shown in (Fig. 3.20 A). PC2 mRNA was seen in CD45RA+ (B 
cells) and CD45RA- fractions (T cells), both in naïve and inflamed LNs (Fig. 3.20 B). 
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Figure 3.20 In vivo PC2 mRNA expression in B and T cells. Rats received an i.pl. CFA injection; 
popliteal LNs were harvested after 24 h and separated into CD45RA- (T cells) and CD45RA+ (B cells) 
using anti-CD45RA microbeads followed by PCR. A: β-Actin mRNA transcripts, pituitary cDNA served 
as positive control. B: PC2 mRNA transcripts, pituitary cDNA served as positive control. Nodes from 
healthy rats served as controls. A DNA marker was run in parallel to estimate the product size in bp. 
Number of independent experiments: n = 6 per group, n = 4 are represented. 
  
 Dissociated LN cells were also separated into CD8+ (cytotoxic T cells) and 
CD8- (mixed B and T helper cells) using anti-CD8a microbeads. PC2 mRNA was 
detected in both CD8- and CD8+ cells from non-inflamed and inflamed LNs (Fig. 3.21 
A). β-Actin transcripts confirming the quality of cDNA and RT-PCR are shown in (Fig. 
3.21 B). 
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Figure 3.21 (bottom previous page) In vivo PC2 mRNA expression in cytotoxic T cells and 
mixed B and T helper cell fractions Rats received an i.pl. CFA injection; popliteal LNs were 
harvested after 24 h and separated into CD8+ (cytotoxic T cells) and CD8- (mix of B and T helper cells) 
fractions using anti-CD8 microbeads followed by PCR. A: PC2 mRNA transcripts, pituitary cDNA 
served as positive control.  Nodes from healthy rats served as controls (0 h).  B: β-Actin mRNA 
transcripts, pituitary cDNA served as positive control.  A DNA marker was run in parallel to estimate 
the product size in bp. Number of independent experiments: n = 6 per group, n = 4 are represented. 
 
3.2.3 Cathepsin L and aminopeptidase B mRNA in lymph node cells  
 
 Several studies demonstrated an additional protease pathway for the 
conversion of POMC into ACTH, β-END, and α-MSH mediated by cathepsin L and 
aminopeptidase B in secretory vesicles (Yasothornsrikul et al., 2003; Funkelstein et 
al., 2008). We observed that cathepsin L mRNA was downregulated in unseparated 
LN cells at 24 h after i.pl. CFA injection in comparison to non-inflamed node cells (0 
h) and was upregulated at 96 h after i.pl. CFA injection (Fig. 3.22). Aminopeptidase B 
mRNA was upregulated at 96 h after i.pl. CFA injection in comparison to 0, 6, and 24 
h (Fig. 3.23).  
  
Figure 3.22 In vivo cathepsin L mRNA expression in lymph nodes Rats received an i.pl. CFA 
injection and popliteal LNs were harvested after 6, 24, and 96 h and from untreated control rats (0 h). 
Cathepsin L transcripts were amplified by qRT-PCR. Data were calculated using the delta-delta CP 
method and represent the mean ± SEM fold change of cathepsin L mRNA levels after CFA injection 
over levels determined in cells from naïve LNs relative to the β-actin levels. Statistical analysis was 
performed using the Kruskal-Wallis test and Dunn’s multiple comparison test. *P < 0.05, n = 8-10 per 
group.  
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Figure 3.23 In vivo aminopeptidase B mRNA expression in lymph nodes Rats received an i.pl. 
CFA injection and popliteal LNs were harvested after 6, 24, and 96 h and from untreated control rats 
(0 h). Aminopeptidase B transcripts were amplified by qRT-PCR. Data were calculated using the delta-
delta CP method and represent the mean ± SEM fold change of aminopeptidase B mRNA levels after 
CFA injection over levels measured in cells from naïve LNs relative to the β-actin levels. Statistical 
analysis was performed using the Kruskal-Wallis test and Dunn’s multiple comparison test. *P < 0.05, 
n = 8-10 per group. 
 
3.2.4 In vitro PC1 and PC2 protein in lymph node cells 
 LN cells were stimulated with IL-4, conA, and IL-4 plus conA separately. 
Immunofluorescence analysis of PC1 and PC2 protein is shown in Fig. 3.24. The 
mean fluorescence intensity per cell in anti-PC1 stained preparations was 
significantly increased within 24 h after stimulation with IL-4 plus conA as compared 
to basal levels in LN cells from healthy rats (n = 6). In anti-PC2-stained preparations 
no significant differences were observed between stimulated and unstimulated LN 
cells. 
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Figure 3.24 In vitro PC1 and PC2 expression in IL-4 and mitogen treated LN cells Primary, naïve 
LN cells were stimulated in vitro with IL-4 and conA for 24 h, and LNs were subsequently harvested. 
Control cells were processed identically but were left without treatment. A+B: Representative anti-PC1 
and PC2 stainings of untreated and stimulated LN cells. C+D: Mean fluorescence intensities ± SEM of 
anti-PC1 and anti-PC2 stained cells are shown. Number of independently performed experiments: n = 
6 per group. Statistical analyses were performed using the Kruskal-Wallis test and Dunn’s multiple 
comparison test. ***P < 0.001. 
 
3.3 Measurement of β-endorphin (β-END) 
 The detection of β-END was established using immunofluorescence (see 
section 2.2.9). The mean β-END fluorescence intensity per cell increased 
significantly over control levels in LN cells treated with conA and conA plus IL-4 (n = 
6, Fig. 3.25 C). IL-4 treatment alone had no effect. The mean number of  β-END-
positive cells above threshold intensities increased significantly over control levels 
after treatment with conA and conA plus IL-4 (n = 6, Fig. 3.25 D), while IL-4 alone 
had no significant effect. In cells treated with conA plus IL-4 the mean number of β-
END-positive cells was significantly higher than in cells treated only with conA (n = 6, 
Fig. 3.25 D). To verify antibody specificity, the β-END antibody was preabsorbed with 
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recombinant Met-enkephalin (MENK) and β-END peptides. Anti-β-END staining of LN 
cells at 24 h after CFA demonstrated a significant reduction of the mean fluorescence 
intensity per cell in the presence of β-END but not of MENK peptide in comparison to 
cells treated with the antibody only (Fig. 3.26). 
 
Figure 3.25 In vitro stimulation of β-endorphin in naïve lymph node cells LNs from healthy rats 
were dissected and cells were incubated with IL-4, conA, and IL-4+conA for 24 h. A: Representative 
anti- β-END staining of stimulated and unstimulated LN cells. B+C: Mean fluorescence intensity ± 
SEM (left) and mean number of cells above threshold ± SEM (right) (n = 6 per group). Statistical 
analysis was performed using the Kruskal-Wallis test and Dunn’s multiple comparison test. **P < 0.01 
and ***P < 0.001: treatments in comparison to untreated control; #P < 0.05: conA compared to 
conA+IL-4. 
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Figure 3.26 Preabsorption experiments of anti-β-END A: Preabsorption with β-END diminished the 
staining of anti-β-END, while the staining was unaffected by preabsorption with MENK. B: Mean 
fluorescence intensity per cell ± SEM; n = 4 per group. Statistical analysis was performed using the 
Kruskal-Wallis test and Dunn’s multiple comparison test. **P < 0.01.  
 
 Next, cellular β-END amounts were determined in B and T cells. We found 
that the amount of β-END in B cells was more than in T cells. These new data extend 
previous findings showing increased cellular β-END levels in lymph node cells 
stimulated in vivo (CFA) and in vitro (IL-4/ConA) (Sitte et al., 2007 and Busch-
Dienstfertig et al., 2012). 
                                                                                                                                       Results 
69 
 
 
 
Figure 3.27 In vivo stimulation of β-END production in lymph node cell subsets by CFA 
injection. Rats received an i.pl. CFA injection, popliteal LNs were harvested after 24 and 96 h and 
separated into CD45RA- (T cells) and CD45RA+ (B cells) using anti-CD45RA microbeads. Nodes from 
healthy rats served as controls (0 h). In cell lysates the β-END-immunoreactivity was determined by 
RIA. Values are given as mean pg END per 107 cells ± SEM. Statistical analyses were performed 
using the Kruskal-Wallis test and Dunn’s multiple comparison test. *P < 0.05; n = 6-8 nodes per time 
point. 
 
3.4 Opioid peptides in mice with chronic arthritis  
 In order to extend our studies to chronic inflammation, the presence of 
endogenous opioid peptides was investigated in a new mouse model of rheumatoid 
arthritis (ACIA-model) (Baddack et al., 2013). Similar to our previous studies in 
inflamed paws (Stein et al., 1990), immunocytes; (Przewlocki et al., 1992), we first 
examined opioid peptide production at the site of primary inflammation (joint), and 
then in the draining LNs. (Fig. 3.28 A), gives an overview of a representative arthritic 
knee joint and the surrounding tissues. The severity of chronic inflammation and joint 
destruction was evaluated by semi-quantitatively scoring hematoxylin and eosin 
(HE)-stained paraffin sections of the inflamed (left) knee joint. The score for chronic 
inflammation reflects synovial hyperplasia, infiltration of the synovium by 
mononuclear cells, and fibrosis. Joint destruction scores were based on pannus 
formation and cartilage and bone erosion. 
 Anti-β-END and anti-CD3 staining was first done on paraffin sections to 
examine opioid peptides in periarticular and popliteal LNs and to investigate the 
localization of β-END. Since the stainings were inconsistent, we subsequently 
studied opioid peptides using RIA.  
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Figure 3.28 HE-staining of the arthritic mouse knee Chronic arthritis was induced by unilateral 
intraarticular injection of methylated bovine serum albumin (mBSA) in Balb/c mice immunized against 
antigen (mBSA) and collagen (bovine collagen II). Ipsilateral knees were collected 64 days after 
induction. Paraffin sections were stained with HE yielding red coloration of soft tissues (muscles, 
tendon, connective tissue, cartilage) and blue staining of cell nuclei. A: Knee joint with popliteal and 
periarticular LNs. B: Magnification of the knee joint with upper triangular and lower triangular region of 
the synovial space. C: Magnification of upper triangular region. D: Magnification of lower triangular 
region. Red arrows in B-D point to sites of dense nuclear staining caused by cellular infiltration. 
 
 
Figure 3.29 HE-staining of healthy knee joint Paraffin sections were prepared from healthy knees 
and those stained with HE. A: Section of the knee joint with upper triangular and lower triangular 
region of the synovial space. B: Magnification of upper triangular region. C: Magnification of lower 
triangular region.  
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 Cell subsets of the LNs draining the arthritic knee were analysed in analogy to 
our investigations of popliteal LNs draining CFA-inflamed rat hind paws. The 
numbers of CD4+ T cells, CD8+ cells, and CD8- cells started to increase after the 
second immunization step, followed by a stronger expansion of all subsets after 
intraarticular (i.a.) injection of mBSA. In the chronic phase, however, cell numbers 
dropped back to the values determined before arthritis induction by i.a. mBSA. Next, 
immunoreactive Met-enkephalin (ir-MENK) levels were determined in cell subsets of 
the draining LNs.  The total amount of ir-MENK showed an elevation over baseline 
levels within 24 h after induction of arthritis by i.a. mBSA in all cell fractions analysed 
(CD4+ T cells, CD4- cells, CD8+ T cells, and CD8- cells). When ir-MENK levels were 
calculated per cell, no substantial changes were observed for the different subsets 
comparing the different time points of ACIA. The baseline values detected per cell in 
CD8+ and CD8- cells were higher than those in CD4+ T cells and CD4- cells.   
 Furthermore, we used RIA and EIA measurements to study opioid peptide 
liberation from the cellular infiltrate of arthritic knee joints. The knee cells were 
explanted and prepared as described (in section 2.2.6). (Fig. 3.30), shows the 
amount of peptides released per knee. The amounts of MENK and β-END peptides 
released into the supernatant were similar as determined by both RIA and EIA. The 
release of Met-enkephalin was not correlated to the cell numbers explanted from 
arthritic knees. The release of β-END was strongly correlated with the cell numbers 
explanted from arthritic knees but showed no correlation with numbers of CD45+ 
cells. 
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Figure 3.30 MENK and β-END liberated from arthritic knee cells Knees were collected 64 days 
after induction of arthritis, and the cellular infiltrate was isolated after tissue digestion. Single cell 
suspensions were kept for 1.5 h at 37 °C and supernatants were harvested to determine the opioid 
peptide release thereafter (MENK with RIA, β-END with EIA). Cells were counted and some animals 
were pooled in case the cell numbers were below 3.0E+06. From the pg-amount of ir-MENK and ir-β-
END determined in RIA and EIA, respectively, the number of biologically active particles was 
calculated based on their molecular mass and on the Avogadro number. The Wilcoxon signed rank 
test was used for a pairwise comparison of ir-β-END released vs. ir-MENK released. The level of 
significance was P < 0.05. 
 
Table 3.1 Correlations between opioid peptide release and cell numbers of explanted knee cells 
Analyses were performed using Spearman correlation; Spearman r is given. *P < 0.05, **P < 0.01. 
Opioid 
peptide 
Number of 
explanted  
knee cells 
Number of 
CD45- knee 
cells in 
explants 
Number of 
CD45+ knee 
cells in 
explants 
ir-MENK 
released 
0.3 0.46 0.15 
ir-β-END 
released 
0.69* 0.76* 0.24 
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4 Discussion 
 
The major findings of this study are the following: 
1. Pomc mRNA expression in naïve lymphocytes seems to be regulated exclusively 
by neither DNA methylation and acetylation nor by miRNA. 
2. Signal sequence-encoding Pomc mRNA is selectively expressed in B cells from 
LNs draining inflamed paws as early as 2 h after inflammation onset. This is 
mimicked by an in vitro cell stimulation model using IL-4. 
3. IL-4 stimulated T cells release a factor that stimulates B cells to express Pomc 
mRNA in a JAK/STAT-mediated manner. 
4. T helper and B cells express PC1 mRNA during inflammation; PC2 mRNA is 
expressed in all cell subsets in inflamed and non-inflamed LN cells. Both processing 
enzymes are upregulated on the protein level in inflammation, while only the PC1 
protein level increases after combined IL-4 plus conA treatment in vitro. 
5. β-END synthesis is elevated in LN cells during paw inflammation in vivo and also 
after combined IL-4 plus conA treatment in vitro.  
 
4.1 Repressive mechanisms 
 
 The human pomc promoter was previously found to be methylated in 
non-POMC-expressing tissues and tumours as well as in normal lymphocytes 
(Newell-Price et al., 2001). However, POMC-expressing tissues and tumours showed 
less or no Pomc gene methylation. Taken together, these findings indicate a 
regulatory role of DNA methylation in Pomc gene expression. To elucidate a possible 
suppression of Pomc expression in naïve rat lymphocytes, we started looking at DNA 
methylation in naïve and stimulated cells from LNs draining rat paws. This question 
was addressed using bisulfite conversion by applying a commercial kit. However, 
according to our sequencing data, the conversion was not efficient. One cause might 
have been the instability of the chemical modification. However, the same or similar 
kits were used with success by others (Hansmann T et al., 2012; Lisanti S et al. 
2013). Another possibility could be a loss of information due to the conversion (by 
erasing all non-methylated cytosines and their replacement by uracil). This could 
have decreased the specificity of PCR primers, even though special methylation 
primer design software was used. Moreover, the PCR products generated 
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simultaneously from different cell types most probably represented amplicons from 
DNAs with different methylation statuses. (Lisanti et al.,2013), used four different 
surrogate assays for global DNA methylation analysis (LUMA Alu, LINE 1, and 
HPLC). In the LUMA assay, DNA samples were digested in parallel with the 
isoschizomer restriction enzymes MspI (unaffected by methylation) and HpaII 
(methylation sensitive). Both recognize the same sequence (CCGG) but cut 
differentially according to the methylation state of the internal cytosine residue. The 
digestion ratio of HpaII/MspI can be determined by pyrosequencing, and the resulting 
ratio is inversely proportional to the methylation content of the sample. In the Alu and 
LINE1 assays, the methylation status of specific cytosine residues in bisulfite-
converted DNA is also quantified by pyrosequencing. Hansmann and colleagues 
(2012) cloned the bisulphite-converted DNA into a vector followed by 
pyrosequencing. Menschikowski and colleagues (2012) used bisulphite conversion 
followed by sequencing and also quantified the methylation status using methylation-
sensitive high-resolution melting analysis. This is a relatively new post-PCR analysis 
used to identify variations in nucleic acid sequences. The method is based on 
detecting small differences in PCR melting (dissociation) curves. The success of 
these studies suggests that it is of advantage not only to directly sequence PCR 
products, but to include further steps, such as cloning and single colony sequencing 
to obtain reliable results. However, in the time frame of the present thesis and for 
financial reasons it was not possible to go for such costly and time consuming 
approaches.  
 Due to the limitations of bisulfite conversion, alternative strategies to study the 
effects of DNA methylation on Pomc gene expression were sought. Menschikowski 
and colleagues (2012) have shown that under control conditions no PLA2R1-mRNA 
(Secretory phospholipase A2 receptor) was detectable after qRT-PCR and agarose 
gel electrophoresis in Jurkat cells (immortalized line of human T lymphocytes) and 
U937 cells. Furthermore, no amplification occurred while using real-time qRT-PCR. 
After exposure of the cells to 5-aza-2´-deoxycytidine(5-aza-dC), which inhibits DNA 
methyltransferase activity and results in DNA demethylation (hypomethylation) and 
gene activation by ‘opening’ chromatin, significant PLA2R1 transcript levels were 
detectable Brueckner and colleagues (2005) investigated the expression of Secreted 
frizzled-related protein 1 (Sfrp1), a gene that is known to be regulated by methylation, 
in human colon carcinoma cells (HCT 116) and human leukaemic pre-B cells (NALM-
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6) using the DNA methyltransferase inhibitor 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-
yl)-3-(1H-indol-3-yl) propionic acid (RG108). In our study RG108 was used to 
investigate the Pomc methylation status because it specifically inhibits CpG 
methylases and is not cytotoxic. In LN cells RG108 failed to elevate Pomc 
expression, but the control gene Sfrp1 was elevated after 15 d of treatment with this 
inhibitor. Besides Sfrp1 there are several genes under control of DNA methylation. 
Another example is the extracellular matrix protein SPARC (secreted protein, acidic, 
rich in cysteine), which showed decreased expression levels in intervertebral discs in 
correlation with increased levels of DNA methylation of the SPARC promoter 
(Tajerian et al., 2011). Brueckner and colleagues (2005) also showed that RG108 
treatment resulted in the demethylation of the tissue inhibitor of metalloproteinases 
(TIMP)-3 gene and the cyclin-dependent kinase inhibitor 2A multiple tumour 
suppressor 1 (P16) gene in HCT 116 cells. Timp-3 mRNA was constitutively 
expressed in LN cells, which indicates that this gene is unmethylated in this cell 
system. Therefore, the Timp-3 gene was not suitable as a control in our experiments, 
and P16 was not tested. Together, our findings suggest that the expression of POMC 
mRNA cannot be induced by interfering with the methylation of the gene, but further 
studies should be undertaken using alternative approaches. 
 Moreover, the mechanism affecting gene expression via histone acetylation 
and deacetylation was investigated. This mechanism relates to the condensation of 
chromatin, which modulates the accessibility of the DNA for transcription factors, etc. 
The histone deacetylase inhibitor trichostatin A was used to treat the LN cells, 
resulting in no upregulation of Pomc mRNA expression. Studies showed that the 
DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine and the histone deacetylase 
inhibitor trichostatin A synergistically upregulate the expression of Maspin in human 
breast cancer cells (MCF-7) (Liao et al., 2014). To rule out that histone deacetylation 
and DNA methylation might act synergistically in the inhibition of Pomc gene 
expression, LN cells were treated with both RG108 and trichostatin A. Nevertheless, 
Pomc mRNA expression in naïve lymphocytes was unaffected by the combined 
treatment, which is similar to the single inhibitor treatments. These findings lead to 
the conclusion that the suppression of the Pomc gene expression in naïve 
lymphocytes cannot be overcome by interfering with the DNA methylation and 
histone acetylation status, indicating that other mechanisms seem to be involved.  
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To study the possible relevance of miRNA in the repression of Pomc mRNA 
expression, knockdown of Dicer was performed using siRNA. Dicer is an important 
endoribonuclease for the processing of most miRNAs. Several transfection reagents 
such as Lipofectamin 2000 and Fugene were tested, but none resulted in a reliable 
uptake of a fluorescent control siRNA (scrambled) by LN cells (data not shown). 
Others demonstrated that the majority of cationic liposome-delivered siRNAs enter 
cells via endocytosis (Lu et al., 2009). In immune cells, the endosomal detention of 
siRNA can result in immune responses via toll-like receptor activation (Sioud et al., 
2005; Yoo et al., 2006). Therefore, immune cells are considered especially hard to 
transfect. Moreover, primary and suspension cells such as our LN cells are generally 
difficult to transfect. An alternative approach to introduce siRNA into cells is the use 
of electroporation. The application of an external electrical field temporarily increases 
cell membrane permeability (Neumann et al., 1982) and delivers siRNA directly into 
the cell cytoplasm. Thus, electroporation can resolve some of the cell-specific 
limitations associated with liposome-based transfection, like the immune response 
induced by siRNA (Sioud et al., 2005). This technique has successfully been used to 
introduce siRNA into primary murine bone marrow-derived macrophages, resulting in 
a target gene knockdown (Wiese et al., 2010). Therefore, the electroporation of 
primary LN cells to knock down Dicer expression using siRNA was established. 
 In the beginning an electroporation system designed and constructed by 
Thorsten Stroh from the group of Prof. Sigmund (Department of Gastroenterology, 
Charité, Berlin) was used, but as this system was not accessible in the long term, the 
experiments were transferred to the Eppendorf Multiporator system with a different 
pulse profile. Similar results were obtained using the two systems. A reliable 
knockdown of Dicer mRNA was achieved after 48 h of electroporation using the 
Eppendorf Multiporator system, 1 µM siRNA, and a pulse of 600 V/25 µs. Studies 
have shown that despite the high efficiency of nucleic acid transfer, electroporation 
can induce high cell mortality (Tsong et al., 1991) Therefore, the number of 
transfected cells was increased from 1 to 10 million, which improved the survival rate 
and the uptake of siRNA. These experimental conditions were comparable to the 
conditions used in other studies (Jensen et al., 2014). Dicer protein knockdown was 
achieved after 5 d using the Eppendorf Multiporator system. At later time points the 
cells were less vital (as determined from microscopic observation of cell shape and 
via the trypan blue exclusion method), and β-actin mRNA levels were decreased (6 
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and 7-day experiments). Thus, the cells might have gone into apoptosis. However, 
knockdown of Dicer at the mRNA and protein level did not result in an upregulation of 
Pomc mRNA levels. As a positive control IL-10 mRNA was investigated, as its 
expression has been shown to be regulated by miRNA. In macrophages for example, 
innate IL-10 expression is promoted by miR-145 through targeting the epigenetic IL-
10 gene silencer histone deacetylase 11 (Lin et al., 2013). In this work, IL-10 mRNA 
levels were undetectable in electroporated LN cells upon Dicer knockdown, while 
untreated and scrambled siRNA-electroporated cells displayed basal IL-10 mRNA 
expression. On the other hand, there are several miRNAs that downregulate IL-10 
expression. For example, the IL-10 level was shown to be inversely correlated with 
the level of Egr 1 (ETS-related gene, an oncogene) induced by has-miR-106a 
expression in Jurkat (immortalized line of human T lymphocytes) and Raji cells 
(lymphoblast-like cells) (Sharma et al., 2009). In CD4+ T cells, IL-10 mRNA levels are 
reduced by let-7 miRNA (Swaminathan et al., 2012). These findings indicate a 
complex regulation of IL-10 mRNA by diverse miRNAs. Pomc mRNA, however, does 
not seem to be affected by this post-transcriptional regulatory mechanism. These 
results lead to the conclusion that miRNA does not play a suppressive role in naïve 
lymphocytes in our setup.  
 
4.2 Expression of POMC 
 
Next, we investigated the transcriptional inducers of Pomc expression. It was 
previously shown that under inflammatory conditions there was an upregulation of 
Pomc mRNA in LN cells (Sitte et al., 2007). In addition, treatment of naïve mixed LN 
cells with IL-4 also resulted in an upregulation of Pomc mRNA levels and this effect 
seemed to be mediated by STAT3 (Busch-Dienstfertig et al., 2012). Moreover, 
STAT3 was also found to be upregulated in a mixed population of LN cells draining 
inflamed paw tissue. Based on these findings, we postulated that cytokines are 
important activators of Pomc mRNA expression in lymphocytes and that the JAK-
STAT pathway is the critical signalling cascade mediating this effect. As these earlier 
studies were performed in a mixed population of LN cells, the present study aimed to 
investigate the effect of cytokine stimulation in subsets of LN cells.  
 
                                                                                                                                Discussion 
78 
 
 To identify the LN cell subsets expressing Pomc mRNA after CFA-induced 
paw inflammation in vivo or after IL-4 exposure in vitro, the mixed LN cell cultures 
were subsequently separated into B and T cells using MACS columns. Two time 
points were investigated (2 h and 24 h). Both treatments induced Pomc mRNA 
expression in B cells after 2 h, while T cells were found to transcribe the Pomc gene 
only after 24 h post IL-4 exposure and not at all after paw inflammation. These 
findings were in contrast to our hypothesis of a predominant Pomc mRNA expression 
in effector T cells. The analysis of peripheral blood leukocytes from healthy donors by 
Anderson and co-workers showed highest Pomc mRNA levels in T helper (Th) cells, 
while cytotoxic T cells, B cells, natural killer cells, monocytes, and granulocytes 
expressed lower levels (Andersen et al., 2005). In contrast to the present study, 
Anderson and colleagues did not measure Pomc exon 2-3 spanning primers but 
determined the level of exon 3 transcripts only. This not only holds the risk of 
amplifying DNA traces instead of mRNA but also touches a long-standing discussion 
on Pomc transcription in non-pituitary tissues. Several previous studies detected so-
called truncated Pomc transcripts in naïve lymphocytes (Buzzetti et al., 1989; Cabot 
et al., 1997; DeBold et al., 1988; Lacaze-Masmonteil et al., 1987; Oates et al., 1988; 
Przewlocki et al., 1992). Others argued that the translation products of truncated 
Pomc transcripts lacking the signal sequence encoded by exon 2 are not processed 
to authentic peptides (Clark et al., 1990; Rees et al., 2002). In the present study, all 
PCR measurements focused on the amplification of exons 2-3. There are not many 
appropriate studies to compare to our findings. (Lansac et al., 2006), investigated 
proenkephalin mRNA expression in the spleen of LPS-treated rats and found an 
elevation in the marginal zone, which harbours B cells, macrophages, and dendritic 
cells. However, no detailed analysis of the proenkephalin mRNA-expressing cell 
subsets in the marginal zone was performed. β-END is expressed by peripheral 
blood B cells after culture with corticotropin-releasing factor and arginine vasopressin 
(Kavelaars  et al., 1989). These findings indicate that full-length Pomc mRNA was 
expressed in B cells, which is in line with our data. This is also supported by the 
findings that a mouse B cell line produced and secreted ACTH (Weigentet al., 1987) 
and that the production of ACTH and β-END in B cells is stimulated with 
corticotropin-releasing factor and lipopolysaccharide (Harbour et al., 1987; 1991). 
However, these studies did not show Pomc gene expression. 
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After we identified B cells as the main Pomc-expressing LN cell subset, they 
were isolated again and directly stimulated with IL-4. However, in the absence of T 
cells no elevation of Pomc mRNA was observed. To detect if this lack of response to 
IL-4 was due to the missing cell-cell contact of B and T cells, T cells were stimulated 
with IL-4, and the supernatant was then added to B cells. These supernatant transfer 
experiments resulted in the expression of Pomc mRNA in B cells, indicating that a 
soluble T cell-derived factor was mediating this gene expression in B cells. In order to 
identify which cytokines were elevated in CFA and IL-4-stimulated T cells and which 
could be responsible for B cell activation, cytokine arrays were performed. The 
cytokines that were elevated in both cases (IL-2, IL-6, and IL-10) were then used to 
stimulate isolated B cells individually and in various combinations, but no Pomc 
mRNA expression was observed. In line with these findings, IL-2 also did not elevate 
Pomc mRNA in AtT-20 cells (a mouse corticotroph cell line) (Katahira et al., 1998; 
Fukata et al., 1989) and had no effect on mixed LN cell cultures (Busch-Dienstfertig 
et al., 2012). In T cell clones, however, Stephanou and colleagues (Stephanou et al., 
1991) found an IL-2-induced elevation of Pomc mRNA expression after 18-24 h, 
which resembles the time span of the IL-4-induced Pomc mRNA expression in LN-
derived T cells shown here. In contrast to our findings in B cells, a combination of LIF 
and IL-6 has been shown to increase the Pomc precursor in corticotroph cells (Li  et 
al., 1999). In summary, we found that IL-4 induces Pomc mRNA expression in B cells 
indirectly in a T cell-dependent manner. However, we could not identify the factor 
released by T cells that stimulated B cells to induce Pomc mRNA. 
 
4.2.1 Pathway and transcription factors 
 
To identify the relevant signalling pathway and active transcription factors 
involved in the IL4-induced, T cell-mediated Pomc mRNA expression in B cells, we 
used cell permeable inhibitors of the JAK-STAT pathway. The IL-4 effect was 
substantially blocked by pyridon 6, a Janus kinase blocker, and by a STAT5 inhibitor, 
but it was not affected using a JAK II inhibitor. These findings indicate that Pomc 
exon 2–3 mRNA upregulation by IL-4 is largely mediated via the JAK-STAT pathway 
involving STAT5, JAK 1, and JAK 3. There are several studies showing that the JAK-
STAT pathway is also involved in regulating pituitary Pomc gene expression. In 
pituitary corticotrophs, LIF induced Pomc gene expression by binding phosphorylated 
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STAT1 and -3 homo- and heterodimers to the promoter (Mynard et al., 2002). LIF 
was found to stimulate Pomc promoter activity through STAT1 and STAT3 
transcription factors (Ray et al., 1996; Bousquet et al., 1997). Li and coworkers (Li et 
al., 1999) demonstrated coordinated regulation of both Pomc and PC1 by LIF and IL-
6. Mouse AtT-20 cells have also been reported to display LIF-induced enhancements 
in ACTH secretion and Pomc transcription (Ray et al., 1996). It was also shown that 
LIF induced Pomc transcription in the placenta of pregnant rats. When differentiated 
rat choriocarcinoma cells (Rcho-1) were treated with LIF or IL-6, they also increased 
the expression of Pomc (Simamura et al., 2010). Besides JAK-STAT, IL-4 also 
activates the phosphoinositide 3-kinase / protein kinase B (Akt) pathway (Keegan et 
al., 1994). This pathway was not addressed in the present study, since it mainly 
regulates translational activity, cell growth, proliferation, differentiation, motility, and 
survival, while transcriptional regulation is not amongst its principal functions. 
Previous studies indicated that the MAPK pathway, which is activated by theAkt 
pathway, is not essential for IL-4-induced Pomc gene expression in lymphocytes 
(Busch-Dienstfertig et al., 2012). This resembles the findings of others in AtT-20 cells 
(Bousquet et al., 1999). 
In the present study, STAT5 as a transcription factor in B cells was found to be 
important for Pomc gene expression after supernatant transfer from IL-4 stimulated T 
cells. In our previous study the role of STATs was also investigated but with another 
approach (Busch-Dienstfertig et al., 2012). By competing with STAT1/3 and STAT5 
binding using decoy oligonucleotides, the IL-4-induced Pomc gene expression was 
reduced, but only STAT1/3 decoy oligonucleotides produced a significant effect. 
STAT5, in addition to STAT6, becomes directly activated by IL-4 in human B (Rolling 
et al., 1996) and murine pro-B cells (Friedrich et al., 1999). This suggests that the 
STAT5 activation in our experiments was not related to the unidentified T cell factor 
but was induced by IL-4. This raises the question of why direct IL-4 stimulation of B 
cells was insufficient for inducing Pomc gene expression if STAT5 is the key 
transcription factor. It seems that STAT5 is not the only critical factor determining 
Pomc transcription. Other factors, including STAT3, may play a concomitant role.  
At this point the exact mechanism or factor that suppresses Pomc expression in 
naïve lymphocytes is unclear. For LN cells stimulated in vitro by IL-4 or in vivo by 
paw inflammation, the current and previous data suggest that STAT3 and -5 have the 
potential to enhance Pomc gene expression in lymphocytes. However, the identity of 
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the regulatory factor inducing Pomc mRNA expression in B cells remains to be 
determined. The present study excluded IL-2, IL-6, and IL-10. However, various 
cytokines were upregulated after CFA and IL-4 treatments, leaving several 
candidates to be investigated. The current findings demonstrated the importance of 
the JAK-STAT pathway for the expression of Pomc mRNA in lymphocytes, which is 
supported by the fact that this is also a crucial pathway in the pituitary and 
hypothalamus.  
 
4.3 POMC-processing enzymes 
 
Another aim of the present study was to demonstrate that lymphocytes express 
the POMC-processing enzymes PC1 and PC2. We hypothesized that their 
expression is upregulated during hind paw inflammation. PC1 mRNA transcripts and 
protein were detectable in LNs draining inflamed paws in vivo. In the in vitro 
experiments, protein expression in IL-4 plus conA-treated cells, but not in non-
inflamed LNs, was observed. Cell subsets expressing PC1 mRNA under 
inflammatory conditions were B and T helper cells, while cytotoxic T cells did not 
express such transcripts. PC2 transcripts were expressed in non-inflamed and 
inflamed LNs, and its protein was significantly upregulated in cells from inflamed LNs, 
although PC2 mRNA expression levels decreased after the induction of inflammation. 
PC2 was expressed with or without IL-4 plus conA treatment, while PC1 was 
expressed only when LN cells were treated. The present findings extend previous 
findings of a co-expression of PC1 and PC2 protein with POMC and β-END in 
circulating leukocytes and inflammatory paw cells (Mousa et al., 2004). Differential 
expression of PC1 and PC2 mRNA was also shown in human pituitary tumours 
(Tateno et al., 2007). In general, basal PC1 and PC2 expression seems to be more 
common in other immune cells than lymphocytes. (LaMendola  et al., 1997) detected 
PC1 mRNA in differentiated macrophages derived from human blood cells. (Vindrola 
et al., 1994), found PC1 protein in alveolar macrophages and in splenic mononuclear 
cells, and PC2 protein was present in polymorphonuclear leukocytes. The present 
findings of an expression of the two PCs in lymphocytes under inflammatory 
conditions are largely in line with findings shown by (Lansac et al., 2006), who 
investigated PC1 and PC2 mRNA expression in rat spleens after LPS treatment. 
They found basal PC1 mRNA expression only in macrophage-rich regions such as 
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the splenic red pulp and the dense paracortical regions of LN tissue. Basal PC2 
mRNA was observed in LN follicles containing densely packed lymphoblasts and B-
lymphocytes but was absent in normal spleen tissue. PC1 and PC2 mRNAs were 
induced after LPS-injection in the germinal centres of spleens, while we found PC1 
mRNA induction but PC2 mRNA downregulation in the LNs draining paw 
inflammation. (Nakashima et al., 2001), investigated the expression of PCs in the 
spleen of diabetic rats. Their analysis showed basal PC1 in both the white (T 
lymphocytes) and red (monocytes and macrophages) pulps and demonstrated an 
increase after streptozotocin-induced diabetes in the white pulp, which is similar to 
the observations of this study.  
As has been shown by others, the expression of PC1 and PC2 in corticotroph 
cells is strongly associated with JAK/STAT pathway activation and can be induced by 
different cytokines. However, IL-4 treatment of naïve LN cells did not result in an 
upregulation of PC1 and PC2 in our experiments. This may be because IL-4 mainly 
activates STAT6. On the other hand, we observed PC1 protein expression after conA 
treatment of LN cells, which was amplified by combined IL-4 plus conA treatment. 
PC2 protein expression remained unaffected by all in vitro treatments. The question 
of whether conA induces PC1 expression via STAT3 activation was not addressed 
but may be of interest in future studies. In summary, the present study demonstrated 
Pomc gene expression and the presence of processing enzymes in LN-derived B 
cells under stimulated conditions, which strongly suggests that such cells are a 
source of bioactive peptides in inflammation. 
Other extracellular signals may explain the downregulation of PC2 mRNA levels 
under inflammatory conditions (Espinosa et al., 2008). For example, in the 
hypothalamus PC2 promoter activity can be regulated by a cAMP response element 
(Espinosa et al., 2008). These authors demonstrated that, by binding to inhibitory G-
protein coupled receptors, morphine induced a decrease in cAMP, resulting in the 
downregulation of PC2 mRNA. A potential inflammatory cytokine that binds to the 
inhibitory G-protein-coupled receptor CCR6 is the chemokine CCL20 (Yang et al., 
2005; Tanaka et al., 1999; Dieu-Nosjean et al., 2000).  
In the present study the mRNA expression of PC1 but not of PC2 coincided with 
the respective protein expression. Others showed that both PC1 and PC2 mRNA and 
protein levels coincided in primary hypothalamic neuronal cultures stimulated with 
leptin (Sanchez et al., 2004). There are several reasons for the poor correlations. 
                                                                                                                                Discussion 
83 
 
First, there are many post-transcriptional mechanisms involved in turning mRNA into 
protein that are not yet sufficiently defined; second, proteins may differ in their in vivo 
half-lives; third, there is a significant amount of noise in both protein and mRNA 
experiments (Baldi et al., 2001; Szallasi et al., 1999). Protein turnover can vary 
significantly depending on a number of different conditions (Glickman et al., 2002). A 
cell can control the rates of degradation or synthesis for a given protein, and there is 
significant heterogeneity, even within proteins that have similar functions (Pratt et al., 
2002; Anderson et al.,1997; Orntoft et al., 2002) found significant correlations. 
However, (Lichtinghagen et al., 2002) found no significant relationship between 
mRNA and protein levels. The discrepancy between PC2 mRNA and protein 
expression may as well suggest that translation is repressed. Such repression has 
previously been reported for the PC2 chaperone 7B2 (Tadros et al., 2011). Moreover, 
the discrepancy between mRNA and protein expression could also be due to false 
positive results. Here, the specificity of PCR products was confirmed via melting 
curve analysis and agarose gel electrophoresis, using pituitary cDNA as a positive 
control. The melting peaks of LN-derived amplicons were identical to those obtained 
from pituitary transcripts. Furthermore, electrophoretic separation of PCR products 
revealed that PC1 and PC2 amplicons detected in LNs matched the expected length 
of the nucleotide sequences and were equal in size to pituitary transcripts. These 
qualitative controls strongly suggest that our PCR products were valid. Although the 
antibody (PC1 and PC2) specificity/sensitivity was previously verified by the provider 
using transfected cells (Ugleholdt et al., 2006), we verified their specificity for our 
method and our cell type using preabsorption assays. Anti-PC1 staining was reduced 
by preabsorbing the antibody with PC1 peptide, but the staining was unaffected by 
preabsorption with PC2 peptide. Similarly, anti-PC2 staining was reduced by 
preabsorbing the antibody with PC2 peptide, while preabsorption with PC1 peptide 
had no effect. Additionally, we also performed specificity tests using western blot 
analysis of the pituitary lysates of PC1 and PC2 knockouts (data not shown).  
In addition to PC1 and PC2, there are other enzymes of importance for POMC 
processing. One of them is carboxypeptidase E (CPE), which functions as a 
regulated secretory pathway sorting receptor for several prohormones, including 
proopiomelanocortin, proenkephalin, and proinsulin. (Zhang et al., 2003) showed by 
mutational studies that full length CPE C-terminal residues are required for the 
regulated secretory pathway. They also showed that sorting CPE to the regulated 
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secretory pathway in endocrine cells is mediated by lipid rafts and that the four C-
terminal residues of CPE, i.e. Thr(431) to Leu-Asn-Phe(434), are required for raft 
association and sorting. In the present study, CPE mRNA and protein expression 
was undetectable in non-inflamed and inflamed LNs as well as in IL-4-stimulated LN 
cells. Since neither CPE mRNA nor protein was detected, we assume that full-length 
CPE is absent in rat LN cells. How lymphocytes compensate for the lack of CPE 
function remains to be determined. 
Other studies demonstrated an additional protease pathway for converting 
prohormones into active peptides mediated by cathepsin L in secretory vesicles 
(Yasothornsrikul et al., 2003) and Arg/Lys aminopeptidase (Yasothornsrikul et al., 
1998). Cathepsin L cleaves proteins at the NH2-terminal side of dibasic sites or 
between the dibasic residues (Yasothornsrikul et al., 1998). In contrast, PC1 and 
PC2 cleave proteins at the COOH-terminal side of dibasic sites, which then requires 
carboxypeptidase E/H (CPE/H) in order to remove COOH-terminal basic residues 
(Azaryan et al.,1994; Zhou et al., 1999; Seidah et al., 2002; Fugère et al., 2005). 
Different aminopeptidases such as cathepsin H (Lu et al., 2012) and aminopeptidase 
B (Yasothornsrikul et al., 2003; Hwang et al., 2007b) have been shown to remove the 
N-terminal basic residues Arg and Lys from peptide intermediates. The investigation 
of cathepsin L knockout mice revealed that cathepsin L is involved in processing 
POMC to produce ACTH, β-END, and α-MSH (Funkelstein et al., 2008). Cathepsin L 
knockout mice have decreases in pituitary ACTH, β-END, and α-MSH, while levels of 
POMC increased. Others showed a co-localization of cathepsin L with β-END, α-
MSH, and ACTH in pituitary secretory vesicles (Hook et al., 2012). We found 
cathepsin L and aminopeptidase B mRNA expression in LNs from healthy rats and 
from animals with paw inflammation. Future studies will have to examine cathepsin L 
and aminopeptidase B proteins. Together these findings indicate that cathepsin L 
and aminopeptidase B may also be involved in POMC cleavage in lymphocytes.  
 
4.4. Measurement of β-endorphin (β-END) 
 
 To match the processing of POMC with the presence of PC1 and PC2 in 
lymphocytes we analysed whether our in vivo and in vitro stimulation models resulted 
in enhanced cellular β-END contents. Immunofluorescence experiments with 
antibodies to β-END showed no elevation of β-END when naïve LN cells were 
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treated with IL-4 alone. To obtain significant opioid peptide levels and cell numbers 
expressing β-END in vitro, we had to prime naïve cells with the mitogen conA, similar 
to others (Hermanussen et al., 2004). An elevation of β-END was observed under the 
same conditions that produced upregulation of PC1 protein expression. These results 
extend our previous findings where increased β-END levels of LN cells were 
measured after in vitro stimulation with IL-4 plus conA (Busch-Dienstfertig et al., 
2012). Then we set out to investigate β-END production in cell subsets of the 
draining LNs of rats with paw inflammation. We found a strong upregulation in B cells 
of inflamed nodes, while the amount of β-END in T cells only slightly increased. 
These data extend our previous findings showing increased cellular β-END levels in 
mixed LN cells in vivo (Sitte et al., 2007) and indicate that B cells are the 
predominant Pomc gene expressing subtype in inflammation. Since these cells were 
found to express PC1 and PC2 alike, it is consistent that β-END elevation was 
determined in B but not in T cells. Nevertheless, these findings were unexpected. 
Previous double-staining experiments with antibodies to β-END and different cell 
phenotypes demonstrated that β-END is mostly present in memory T cells (Cabot et 
al., 1997). However, in line with our findings, others investigated the cleavage 
products of POMC in B cells (Harbour et al., 1991; 1987). These authors found that 
stimulating B cells with corticotropin-releasing hormones or viruses produced ACTH 
1-39 and β-END, while in LPS-stimulated cells cleavage products of ACTH 1-39 
(ACTH 1-22 to 1-26) and β-END (gamma-END) predominated. LPS activated an 
additional processing enzyme with an activity pH of 5, which resembles the optimal 
pH of PC2 (Li et al., 2003). Together, these findings suggest that B cells are a source 
of β-END production, and they support that Pomc gene expression and precursor 
processing are independently regulated in lymphocytes. 
 
4.5 Opioid peptides in arthritis 
 
In order to compare the above findings to a different model of inflammation 
(ACIA), the expression of opioid peptides in explanted cells of arthritic knees was 
investigated. As expected, the amount of β-END determined in the supernatant of 
such cells was generally related to the cell number, but it surprisingly did not 
correlate with the number of immune cells in the preparation. This is in contrast to 
previous findings obtained in acutely inflamed hind paws (Rittner et al., 2001; Brack 
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et al., 2004). It is possible that β-END may be expressed in other cells under chronic 
conditions than in acute inflammation. Mousa and colleagues have shown that, 
besides macrophages and T cells, fibroblast-like synoviocytes also stained positive 
for β-END in tissue biopsies from patients with chronic rheumatoid arthritis. In some 
biopsies, fibroblast-like synoviocytes and plasma cells represented the predominant 
β-END-containing cell populations (Mousa et al., 2007). Our data suggest that in 
ACIA the expression of β-END also occurs in non-immune cells. 
The cellular levels of met-enkephalin correlated significantly with cell numbers 
from explanted knee cells. Correlations with the number of CD45+ cells were also 
strong but not statistically significant; the strongest correlation was found for the 
number of non-immune cells. Overall, the presence of this opioid peptide in immune 
and non-immune cells is in agreement with previous findings of met-enkephalin-
positive lymphocytes, macrophages, and plasma cells in tissue biopsies from 
rheumatoid arthritis patients and with met-enkephalin-positive fibroblasts in tissue 
biopsies from osteoarthritis patients (Mousa et al., 2007). The liberation of met-
enkephalin, however, did not correlate with cell numbers of explanted knee cells. It is 
possible that the extent of met-enkephalin release differs between the cell subsets 
(lymphocytes, macrophages, plasma cells, and fibroblasts). However, relative to the 
molecular mass of the two peptides (571.65 Da for met-enkephalin and 3466.07 Da 
for β-END), the net amount of biologically active peptides determined here was 
similar.  
Finally, we compared opioid peptides in explanted cells of arthritic knees and 
LNs. In knee cells we found that the amount of Met-enkephalin increased after 
induction of arthritis but decreased at later stages. This is in contrast to LN cells, 
where no substantial changes were observed between early and later stages. This 
may indicate that opioid peptides in the knee joint are stimulated by different 
mechanisms in comparison to LNs. Previous studies from (Baddack et al., 2013) 
showed the formation of a new LN in close proximity to the knee joint in this model. 
Therefore, we investigated opioid peptides in the synovial space, popliteal LNs, and 
periarticular LNs. The tissue slices were deparaffinised for antigen retrieval. Various 
parameters were altered, but the results were inconsistent. There could be various 
reasons for this. Proteolytic digestion of fixed paraffin sections can increase the 
stainability chances of cytoplasmic antigens (Nemes et al., 1983; Tanaka et al., 
1984) demonstrated that pre-treatment with hyaluronidase was necessary for 
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staining surface antigens of lymphocytes, whereas (Sato et al., 1986) demonstrated 
that pre-treatment with the enzyme was not necessary. The staining also largely 
depends on the fixation procedure (Fisher et al., 1994). Some reports suggest that 
antigen retrieval immunohistochemistry gives good results (Shi et al., 1997) but 
standardization is required for this method (Taylor et al., 1994, 2006; Shi et al., 
2013). For example, standardization of temperature, duration of heating, and pH 
value of the buffer are major factors that influence the effectiveness of staining (Shi 
et al., 2007). Future experiments will have to be performed to optimize these 
conditions. 
 
4.6 Conclusion 
 
 From the present studies we can conclude that the regulation of Pomc in 
lymphocytes differs from the pituitary. Pomc in lymphocytes is expressed only in B 
cells under conditions such as paw inflammation and in vitro stimulation of LN cells 
with IL-4. Our experiments suggest that neither DNA methylation, acetylation, nor 
miRNA are involved in the repression of the Pomc gene in naïve cells. Although the 
key factor triggering Pomc mRNA expression in B cells remains unknown, there is an 
indication that it is a cytokine acting through the JAK/STAT pathway. Both in vitro and 
in vivo experiments show that the proteolytic processing of POMC into β-END in 
lymphocytes involves PC1, PC2, cathepsin L, and aminopeptidase B. However, 
unlike in the pituitary, it does not show involvement of CPE. We found that both β-
END and POMC are produced in B cells. These findings may help develop novel 
strategies for pain therapy in inflammatory diseases by boosting the innate opioid 
peptide production in immune cells. 
 
4.7 Future experiments 
  
 Future experiments will have to address remaining questions regarding the 
exact mechanism that suppresses Pomc gene expression in naïve lymphocytes, the 
factor released by T cells that stimulates B cell production of Pomc mRNA, the role of 
cathepsin L and aminopeptidase B in POMC cleavage in lymphocytes, the lack of 
CPE in lymphocytes, the cellular expression of β-END in chronic arthritis, and the 
differential production and release of β-END and Met-enkephalin. 
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